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Foreword	  
	  
Looking	  back	  at	  five	  years	  as	  a	  medical	  student	  global	  health	  realated	  topics	  has	  only	  been	  a	  very	  small	  
part	  of	  the	  curriculum.	  Interestingly	  enough	  when	  looking	  at	  the	  situation	  in	  the	  world	  today	  where	  
global	  health	  related	  questions	  are	  central	  among	  others	  due	  to	  increased	  globalisation	  and	  an	  increasing	  
number	  of	  asylum	  seekers	  and	  refugees	  as	  a	  consequense	  of	  poverty,	  conflicts	  and	  accelerating	  climat	  
changes.	  Global	  health,	  whether	  we	  realize	  it	  or	  not,	  is	  becoming	  an	  important	  part	  of	  our	  daily	  life.	  
Throughout	  the	  past	  five	  years	  as	  a	  medical	  student	  I	  have	  got	  the	  chance	  to	  experience	  six	  different	  
health	  autorities	  in	  Sub-­‐Saharan	  countries,	  including	  hospitals	  and	  clinics.	  Much	  attention	  is	  drawn	  to	  the	  
great	  infectious	  burden	  of	  malaria,	  tuberculosis	  and	  HIV.	  On	  the	  other	  hand	  little	  attention	  has	  been	  upon	  
mother	  to	  child	  transmission	  of	  hepatits	  B	  virus,	  even	  during	  a	  semester	  in	  Gynaecology	  and	  Obstetrics	  in	  
Zimbabwe,	  the	  subject	  was	  never	  discussed.	  Knowing	  the	  epidemiology	  and	  the	  burden	  of	  the	  disease	  I	  
would	  like	  to	  gain	  more	  knowledge	  about	  the	  virus	  and	  the	  transmission	  between	  mother	  and	  child.	  
Moreover,	  I	  would	  like	  to	  better	  understand	  prevention	  strategis	  and	  why	  vaccination	  coverage	  
conserning	  hepatitis	  B	  virus	  show	  great	  differences	  among	  countries	  and	  how	  the	  design	  of	  international	  
guidelines	  is	  been	  developed.	  
	  
I	  would	  like	  to	  express	  my	  gratitude	  to	  my	  supervisor	  Tore	  Gutteberg,	  for	  the	  useful	  comments,	  remarks	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AASLD	   	  
American	  Association	  for	  the	  Study	  of	  Liver	  Diseases.	  A	  non-­‐profit	  organization	  of	  scientists	  and	  
health	  care	  professionals	  committed	  to	  preventing	  and	  curing	  liver	  disease	  
Acute	  HBV	  infection	   	  
Initinal	  infection,	  often	  self-­‐limiting	  and	  characterized	  by	  acute	  inflammation	  and	  hepatocellular	  	  
necrosis.	  Clinically	  it	  presents	  with	  different	  signs	  and	  symptoms,	  including	  nonspecific	  	  
symptoms	  such	  as	  anorexia,	  nausea	  or	  malaise	  and	  clinical	  hepatitis	  with	  jaundice	  
Adaptive	  immune	  system	  	  
Also	  know	  as	  the	  acquired	  immune	  system.	  Characterized	  by	  highly	  specialized	  cells	  and	  
processes	  that	  eliminate	  or	  prevent	  pathogen	  growth	  and	  create	  immunological	  memory.	  I	  
consist	  of	  antigenpresenting	  cells,	  such	  as	  B-­‐	  and	  T-­‐cells.	  The	  proses	  of	  acquired	  immunity	  are	  
the	  basis	  of	  vaccination	  
AIDS	   	   	   	  
Acquired	  immunodeficiency	  syndrome.	  AIDS	  is	  following	  an	  initial	  infection	  with	  human	  
immunodeficiency	  virus.	  As	  the	  infection	  progresses,	  it	  interferes	  with	  the	  immune	  system,	  
increasing	  the	  risk	  of	  common	  opportunistic	  infections	  
ALT	  
Alanine	  transferase,	  also	  called	  alanine	  aminotransferase	  (ALAT).	  An	  enzyme,	  commonly	  found	  	  
in	  the	  liver,	  but	  also	  present	  in	  various	  body	  tissue.	  	  Hepatocellular	  injury	  will	  release	  ALT	  into	  	  
the	  circulation	  system.	  ALT	  will	  typically	  fluctuate	  in	  persons	  with	  chronic	  hepatitis	  B	  infection	  	  
and	  it	  require	  several	  measurements	  to	  determine	  the	  trend.	  Norwegian	  reference	  ranges:	  female	  	  
10-­‐45	  IU/L,	  male	  10-­‐70	  IU/L	  
Antigen	  
	   A	  substance/molecule	  capable	  of	  inducing	  an	  immune	  response	  to	  produce	  antibodies	  against	  it	  	  
Antibody	  
Also	  known	  as	  immunoglobulin	  (Ig).	  Mainly	  produces	  by	  plasma	  cells	  that	  are	  used	  by	  the	  
immune	  system	  to	  identify	  and	  neutralize	  pathogens	  such	  as	  bacteria	  and	  viruses.	  The	  antibody	  
recognizes	  the	  antigen	  
APRI	   	  
Aspartate	  aminotransferase-­‐to-­‐platelet	  ratio	  index.	  An	  index	  to	  estimate	  hepatic	  fibrosis	  based	  
on	  a	  formula	  derived	  from	  aspartate	  aminotransferase	  (AST)	  and	  platelet	  concentrations	  
ART	   	   	   	  
Antiretroviral	  therapy.	  Medications	  to	  suppress	  virus	  replication	  
anti-­‐HBc	  	   	  
Hepatitis	  B	  core	  antibody.	  Anti-­‐HBc	  antibodies	  are	  detectable	  in	  both	  acute	  and	  chronic	  infection,	  
thus	  not	  neutralizing	  antibodies	  
anti-­‐HBe	  	   	  
	   v	  
Antibody	  to	  hepatitis	  B	  e	  antigen.	  Detected	  in	  persons	  with	  lower	  levels	  of	  HBV	  replication,	  could	  
also	  be	  in	  HBeAg-­‐negative	  individuals	  (HBV	  that	  does	  not	  express	  HBeAg)	  
anti-­‐HBs	  	   	  
Antibody	  to	  hepatitis	  B	  surface	  antigen.	  Immunologic	  response	  to	  HBV	  vaccination	  or	  during	  a	  
recovery	  phase	  from	  an	  acute	  infection.	  Indicating	  immunity	  booster	  dose	  
Case	  fatality	  rate	  
In	  epidemiology,	  a	  case	  fatality	  rate	  is	  the	  proportion	  of	  deaths	  within	  a	  designated	  population	  of	  
“cases”,	  over	  the	  progression	  of	  the	  disease	  
cccDNA	   	  
Covalently	  closed	  circular	  DNA.	  Mini-­‐chromosome	  that	  serves	  as	  the	  template	  for	  the	  viral	  
transcription,	  during	  viral	  replication	  cycle	  of	  HBV	  
Cellular	  mediated	  immunity	  
Immune	  response	  involving	  activation	  of	  phagocytes,	  antigen-­‐specific	  cytotoxic	  T-­‐lymphocytes	  	  
and	  the	  release	  of	  various	  cytokines	  in	  response	  to	  an	  antigen	   	   	  
CHB	   	  
Chronic	  hepatits	  B.	  A	  chronic	  infection	  with	  hepatitis	  B	  virus.	  Defined	  as	  persistence	  of	  hepatitis	  	  
B	  surface	  antigen	  (HBsAg)	  for	  at	  least	  six	  months,	  following	  an	  acute	  infection	  with	  HBV	  
CMIA	  
Chemiluminescent	  Microparticle	  Immunoassay.	  Serological	  diagnostic	  technique	  to	  detect	  	  
antigen	  in	  blood	  or	  serum.	  The	  technique	  is	  based	  on	  the	  characteristics	  of	  antigens	  binding	  to	  	  
commercially	  produced	  antibodies	  with	  chemiluminescentsantigen	  
CDC	   	  
Centers	  for	  Disease	  Control	  and	  Prevention.	  Leading	  national	  public	  health	  institute	  of	  the	  United	  	  
States.	  Its	  main	  goal	  is	  to	  protect	  public	  health	  and	  safety	  through	  the	  control	  and	  prevention	  of	  	  
disease,	  injury,	  and	  disability	  
DTP	   	   	   	  
Diphteria-­‐tetanus-­‐pertussis.	  A	  vaccine	  made	  of	  diphtheria	  toxoid,	  tetanus	  toxoid,	  and	  pertussis	  
vaccine	  given	  in	  one	  dose	  
EASL	   	   	   	  
European	  Association	  for	  the	  Study	  of	  the	  Liver.	  Founded	  to	  promote	  research	  on	  the	  liver	  and	  its	  
pathology	  and	  to	  improve	  therapy	  for	  liver	  disorders	  
GAVI	   	  
The	  Vaccine	  Alliance	  (formerly	  the	  Global	  Alliance	  for	  Vaccines	  and	  Immunization).	  A	  public-­‐	  
private	  global	  health	  partnership	  committed	  to	  increasing	  access	  to	  immunization	  in	  poor	  
countries	  
HBcAg	  	   	  
Hepatitis	  B	  core	  antigen.	  HBV	  core	  protein	  that	  is	  coated	  with	  HBsAg,	  thus	  not	  detectable	  in	  free	  	  
form	  in	  serum	  	  
HBeAg	  	   	  
Hepatitis	  B	  e	  antigen.	  Viral	  protein,	  usually	  a	  marker	  of	  a	  highly	  replicative	  phase	  of	  the	  virus	  
	   vi	  
HBIG	  	   	   	   	  
Hepatitis	  B	  immune	  globulin.	  A	  solution	  of	  antibodies	  that	  are	  able	  to	  attach	  to	  the	  hepatitis	  B	  
viruses	  and	  cause	  them	  to	  be	  destroyed.	  HBIG	  will	  prevent	  infection	  until	  the	  vaccine	  takes	  effect	  
HBsAg	  	   	  
Hepatitis	  B	  surface	  antigen.	  Glycoprotein	  attached	  to	  the	  envelope.	  May	  be	  detected	  in	  the	  blood	  
	  in	  an	  acute	  or	  chronic	  hepatitis	  B	  infection	  as	  one	  of	  several	  viral	  proteins	  
HBV	  	   	   	   	  
Hepatitis	  B	  virus	  	  
HBV-­‐DNA	   	  
Hepatitis	  B	  virus	  genom.	  May	  be	  detected	  and	  quantified	  in	  serum.	  HBV-­‐DNA	  found	  in	  serum	  
increases	  proportionally	  with	  circulating	  viral	  particles.	  Measured	  in	  IU/mL,	  1	  UL/mL	  ~	  5,3	  	  
copies/mL.	  Levels	  below	  15	  IU/mL	  are	  undetectable	  for	  laboratory	  assays	  
HCC	   	   	   	  
Hepatocellular	  carcinoma.	  Cancer	  with	  origin	  from	  the	  hepatocytes	  
HCV	  	   	   	   	  
Hepatitis	  C	  virus	  	  
HEELP	   	   	   	  
Haemolysis	  elevated	  liver	  enzymes	  and	  low	  platelet	  syndrome.	  It	  represents	  a	  severe	  form	  of	  
preeclampsia.	  Associate	  with	  serious	  hepatic	  manifestations,	  including	  infarction,	  haemorrhage,	  
and	  rupture	  
HIV	  	   	   	   	  
Human	  immunodeficiency	  virus.	  A	  retrovirus	  that	  causes	  HIV	  infection	  and	  over	  the	  time	  AIDS.	  
Humoral	  immunity	  
	   Immune	  response	  that	  refers	  to	  antibody	  production	  following	  Th2	  activation	  
HLA	  
Human	  leukocyte	  antigen.	  A	  cell-­‐surface	  protein	  responsible	  for	  the	  regulation	  of	  the	  immune	  
system	  
Horizontal	  transmission	  
Here:	  transmission	  of	  an	  infectious	  disease	  from	  one	  individual	  to	  another,	  by	  either	  direct	  
contact	  or	  indirect	  contact	  	  
IgG	  anti-­‐HBc	   	  
Immunoglobulin	  G	  to	  hepatitis	  B	  core	  protein.	  Subclass	  of	  anti-­‐HBc	  indicating/detectable	  in	  past	  
or	  current	  infection	  
IgM	  anti-­‐HBc	  	   	  
Immunoglobulin	  M	  to	  hepatitis	  B	  core	  protein.	  Subclass	  of	  anti-­‐HBc	  indicating	  acute	  hepatitis	  B,	  	  
but	  can	  be	  detected	  in	  active	  chronic	  HBV	  
Innate	  immune	  system	   	  
Involves	  of	  complement,	  phagocytes	  and	  natural	  killer	  cells.	  In	  contrast	  to	  the	  adaptive	  immune	  
system,	  the	  initiate	  immune	  system	  lack	  immunological	  memory	  and	  will	  respond	  in	  the	  same	  
way	  with	  each	  infection	  
	   vii	  
MTCT	  
Mother	  to	  child	  transmission.	  A	  vertically	  transmitted	  infection	  is	  an	  infection	  caused	  by	  bacteria,	  
viruses,	  or	  in	  rare	  cases,	  parasites	  transmitted	  directly	  from	  the	  mother	  to	  an	  embryo,	  fetus,	  or	  
baby	  during	  pregnancy	  or	  childbirth	  
MSIS	   	  
Norwegian	  Surveillance	  System	  for	  Communicable	  Diseases.	  Microbiological	  laboratories	  
analyzing	  specimens	  from	  humans,	  all	  doctors	  in	  Norway	  are	  required	  by	  law	  to	  notify	  cases	  	  
of	  certain	  diseases,	  included	  hepatitis	  B,	  to	  the	  MSIS	  central	  unit	  at	  Norwegian	  Institute	  of	  Public	  
Health	  
NIT	  	   	   	   	  
Non-­‐invasive	  tests.	  	  
NF-­‐kB	   	   	   	  
Nuclear	  factor-­‐kappaB.	  A	  protein	  complex	  that	  controls	  transcription	  of	  DNA,	  cytokine	  
production	  and	  cell	  survival	  
NTCP	  
	   Sodium-­‐taurocholate	  co-­‐transporting	  polypeptide.	  A	  liver	  bile	  acid	  transporter	  
Occult	  infection	   	  
Occult	  HBV	  infection.	  Typically	  individuals	  who	  have	  cleared	  the	  hepatitis	  B	  surface	  antigen,	  	  
HBsAg-­‐negative,	  but	  can	  have	  low	  levels	  of	  HBV-­‐DNA	  (<200	  IU/mL)	  
PCR	   	   	   	  
Polymerase	  chain	  reaction.	  A	  method	  used	  in	  molecular	  biology	  to	  amplify	  a	  single	  copy	  or	  a	  few	  
copies	  of	  a	  piece	  of	  DNA	  to	  millions	  of	  copies	  of	  that	  particular	  DNA	  sequence	  
PEP	   	   	   	  
Post	  exposure	  prophylaxis.	  Combination	  of	  HBIG	  and	  a	  monovalent	  HepB	  vaccine	  given	  within	  24	  
hours	  of	  birth	  
Polymorphism	   	   	  
Here:	  genetic	  polymorphism.	  Occurrence	  in	  the	  same	  population	  of	  two	  or	  more	  alleles	  at	  one	  
locus,	  each	  with	  different	  frequency	  
RAVN	  
Resistance	  against	  Antivirals	  in	  Norway.	  National	  surveillance	  system	  including	  following	  
viruses:	  influenza	  virus,	  HIV-­‐1,	  hepatitis	  B	  virus,	  cytomegalovirus	  and	  herpes	  simplex	  virus,	  with	  
focus	  on	  the	  HIV	  and	  influenza	   	  
RNA	  	   	   	   	  
Ribonucleic	  acid.	  Polymeric	  molecule	  consisting	  of	  nucleic	  acids	  found	  as	  a	  single-­‐strand.	  	  
Hepatitis	  C	  virus	  encode	  its	  genetic	  information	  using	  RNA	  genome	  
Transient	  elastography	   	  
FibroScan.	  A	  technique	  to	  measure	  grade	  of	  liver	  fibroses	  through	  the	  detection	  of	  liver	  stiffness	  
using	  ultrasound	  
TDF	  	   	   	   	  
	   viii	  
Tenofovir	  disoproxil	  fumarate.	  Antiretroviral	  medication	  used	  to	  prevent	  and	  treat	  HIV/AIDS	  and	  
to	  treat	  chronic	  hepatitis	  B	  
TORCH	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Toxoplasmosis,	  other	  (syphilis),	  rubella,	  cytomegalovirus,	  herpes	  simplex	  virus.	  A	  group	  of	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  perinatal	  infections	  that	  may	  have	  similar	  clinical	  presentations,	  including	  rash	  and	  ocular	  	  	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  findings	  	  	  	  	  	  
UNICEF	  
	  United	  Nations	  Children´s	  Emergency	  Fund.	  A	  program	  that	  provides	  long-­‐term	  humanitarian	  
and	  developmental	  assistance	  to	  children	  and	  mothers	  in	  developing	  countries	   	  
Vertical	  transmission	  
Here:	  Transmission	  of	  an	  infectious	  disease	  from	  parent	  to	  offspring,	  such	  as	  perinatal	  	  	  	  
transmission	   	  
VL	   	  
Viral	  load.	  Hepatitis	  B	  viral	  load	  in	  serum,	  same	  as	  HBV	  DNA.	  Measured	  in	  IU/mL	  
WHO	  	   	   	   	  
World	  Health	  Organization.	  Specialized	  agency	  in	  United	  Nations	  that	  is	  concerned	  with	  






















	   ix	  
Summary	  
 
Globally,	  mother	  to	  child	  transmission	  (MTCT)	  of	  hepatitis	  B	  virus	  (HBV)	  is	  the	  major	  route	  of	  
transmission,	  while	  horizontal	  transmission,	  between	  adults,	  dominates	  in	  countries	  such	  as	  Norway.	  2	  
billion	  people	  worldwide	  have	  serologic	  evidence	  of	  past	  or	  present	  infection	  with	  hepatitis,	  emphasizing	  
that	  this	  infectious	  disease	  should	  be	  acknowledged	  as	  a	  global	  health	  problem	  in	  line	  with	  HIV,	  
tuberculosis	  and	  malaria.	  	  MTCT	  of	  hepatitis	  B	  is	  the	  most	  important	  factor	  for	  developing	  a	  persistent	  
infection,	  thus	  the	  risk	  of	  chronicity	  is	  inversely	  proportional	  with	  age,	  and	  most	  of	  the	  newborns	  (90%),	  
to	  hepatitis	  B	  positive	  mothers,	  will	  get	  the	  virus	  without	  any	  prevention	  strategies.	  This	  is	  leading	  us	  to	  
the	  focus	  of	  this	  assignment	  upon	  the	  prevention	  of	  mother	  to	  child	  transmission	  of	  hepatitis	  B.	  Despite	  
an	  existing	  and	  effective	  vaccine	  and	  immunoprophylaxis	  regime,	  the	  implementation	  of	  
immunoprophylaxis	  in	  developing	  countries	  has	  been	  challenging.	  The	  infections	  burden	  of	  the	  disease	  is	  
well	  established	  in	  highly	  endemic	  East	  Asia	  where	  the	  prevalence	  is	  estimated	  to	  be	  above	  5%	  and	  the	  
virus	  is	  one	  of	  the	  major	  infectious	  causes	  of	  death.	  Vietnam	  and	  Cambodia	  are	  two	  high	  endemic	  
countries	  facing	  great	  challenges	  concerning	  the	  combat	  against	  MTCT	  of	  the	  virus.	  The	  main	  focus	  on	  
prevention	  strategies	  should	  be	  to	  obtain	  better	  coverage	  of	  the	  monovalent	  HBV	  vaccine	  and	  HBV	  
immunoglobulin,	  timely	  after	  birth.	  Additionally,	  antiviral	  therapies	  to	  decrease	  the	  hepatitis	  B	  viral	  
concentrations	  in	  the	  mother	  before	  delivery	  will	  be	  important	  in	  future.	  This	  assignment	  is	  a	  literature	  
study	  and	  gives	  an	  introduction	  to	  the	  virus	  and	  the	  major	  routes	  of	  MTCT.	  Moreover,	  it	  looks	  into	  current	  
guidelines	  by	  WHO	  and	  Centres	  for	  Disease	  Control	  and	  Prevention	  (CDC)	  and	  discusses	  prevention	  
strategies,	  and	  also	  gives	  an	  overview	  on	  the	  situation	  in	  Norway	  today.	  It	  will	  point	  out	  research	  gaps	  
and	  the	  need	  for	  policy	  changes,	  including	  better	  national	  plans	  for	  serosurveys.	  However,	  the	  question	  of	  
how	  to	  prevent	  MTCT	  of	  HBV	  is	  more	  intricate	  than	  it	  seemingly	  looks	  like,	  there	  are	  many	  challenges	  and	  
factor	  to	  take	  into	  consideration,	  factor	  that	  are	  not	  so	  evident	  for	  decision	  makers	  living	  in	  our	  part	  of	  
the	  world.	  	  
	  
Finally,	  without	  better	  control	  of	  the	  transmission	  between	  mother	  and	  child	  of	  the	  virus	  in	  high	  endemic	  
East	  Asia,	  control	  at	  a	  global	  level	  will	  be	  difficult	  to	  obtain.	  Hopefully	  this	  assignment	  can	  contribute	  to	  






According	  to	  the	  most	  recent	  estimates	  form	  the	  World	  Health	  Organization	  (WHO),	  about	  240	  million	  
people	  are	  chronically	  infected	  with	  hepatitis	  B	  virus	  (HBV)	  [1,	  2],	  3,6%	  of	  the	  world´s	  population.	  An	  
estimated	  686	  000	  people	  will	  annually	  die	  as	  a	  consequence	  of	  complications	  to	  the	  HBV	  infection,	  either	  
acute	  or	  chronic	  [3].	  It	  is	  further	  estimated	  that	  2	  billion	  people	  have	  serologic	  evidence	  of	  past	  or	  present	  
infection,	  with	  East	  Asia	  as	  one	  of	  the	  regions	  in	  the	  world	  with	  highest	  prevalence	  (<5	  %)	  [4].	  The	  virus	  
is	  one	  of	  the	  major	  infectious	  cause	  of	  death	  in	  the	  region,	  ahead	  of	  malaria,	  tuberculosis	  and	  Human	  
Immunodeficiency	  Virus	  (HIV)	  [5].	  
	  
In	  Asia	  vertical	  transmission	  of	  HBV,	  also	  known	  as	  mother	  to	  child	  transmission	  (MTCT),	  is	  the	  major	  
route	  of	  transmission	  [6].	  According	  to	  previous	  studies	  [7]	  vertical	  transmission,	  particularly	  during	  the	  
perinatal	  period,	  is	  pointed	  out	  to	  be	  the	  most	  important	  phase	  for	  the	  prevention	  strategies	  against	  
developing	  a	  chronic	  hepatitis	  B	  (CHB)	  infection.	  	  Without	  vaccination	  about	  50%	  of	  the	  children,	  with	  
Hepatitis	  B	  surface	  antigen	  (HBsAg)	  positive	  mothers,	  will	  get	  the	  virus.	  If	  the	  transmission	  occurs	  during	  
the	  perinatal	  period,	  and	  with	  a	  HBsAg	  and	  hepatitis	  B	  e	  antigen	  (HBeAg)	  positive	  mother,	  90%	  will	  
develop	  a	  chronic	  HBV	  infection	  without	  immunoprofylaxis	  [6,	  8,	  9].	  In	  contrast,	  the	  risk	  of	  a	  chronic	  HBV	  
infection	  decreases	  to	  30%	  if	  the	  transmission	  takes	  place	  at	  the	  age	  of	  between	  one	  and	  four.	  
Furthermore,	  horizontal	  transmission	  to	  a	  healthy	  adult	  will	  in	  less	  than	  5%	  of	  the	  infections	  develop	  into	  
a	  chronic	  infection	  [4].	  This	  gives	  us	  an	  inversely	  proportional	  risk	  of	  developing	  chronic	  HBV	  infection	  to	  
the	  age	  at	  time	  of	  exposure,	  which	  will	  be	  discussed	  further	  below.	  China	  is	  a	  good	  example	  to	  emphasise	  
the	  consequences	  of	  perinatal	  transmission.	  The	  country	  has	  a	  94%	  coverage	  of	  a	  tree-­‐dose	  HBV	  
vaccination,	  but	  MTCT	  still	  accounts	  for	  40-­‐50%	  of	  new	  infections	  [10].	  Given	  what	  we	  know	  about	  90%	  
risk	  of	  developing	  a	  CHB	  infection	  if	  transmission	  occurs	  perinatally,	  it	  is	  obvious	  that	  HBV	  still	  remain	  a	  
major	  public	  health	  problem,	  as	  newly	  published	  literature	  also	  points	  out	  [8,	  11,	  12].	  This	  again	  
emphasises	  the	  importance	  of	  preventing	  MTCT	  as	  well	  as	  immunization	  [13],	  which	  this	  assignment	  will	  
try	  to	  cover.	  	  Looking	  at	  existing	  global	  and	  regional	  prevention	  strategies	  to	  battle	  Human	  
Immunodeficiency	  virus	  	  (HIV),	  tuberculosis	  and	  malaria,	  the	  fight	  against	  MTCT	  of	  HBV	  seems	  to	  be	  
coming	  in	  second	  line	  [12,	  14].	  However,	  WHO	  newly	  launched	  a	  plan	  which	  sets	  targets	  for	  2020,	  it	  
includes	  among	  others	  90%	  childhood	  vaccine	  coverage	  for	  HBV	  and	  50%	  birth	  dose	  vaccine	  coverage	  to	  




Consider	  the	  prevention	  of	  MTCT	  as	  an	  important	  component	  of	  reducing	  the	  global	  burden	  of	  CHB	  
infection	  leads	  to	  the	  focus	  of	  this	  assignment.	  The	  main	  effort	  will	  be	  to	  look	  at	  the	  prevention	  strategies	  
of	  HBV	  infection	  in	  the	  perinatal	  period.	  I	  will	  look	  into	  international,	  as	  well	  as	  national	  guidelines	  in	  
Norway.	  To	  better	  understand	  the	  great	  differences	  in	  epidemiology	  of	  the	  virus	  I	  will	  look	  into	  the	  
situation	  in	  East	  Asia,	  particularly	  in	  Vietnam	  and	  Cambodia.	  As	  a	  base	  I	  have	  used	  the	  WHO	  database	  to	  
2	  
	  find	  data	  upon	  vaccination	  rates	  in	  these	  two	  countries.	  This	  will	  hopefully	  give	  the	  readers	  a	  better	  
understanding	  of	  how	  the	  global	  situation	  concerning	  the	  virus	  can	  vary	  so	  greatly.	  	  A	  basic	  
understanding	  of	  the	  hepatitis	  B	  virology,	  host	  immune	  response	  and	  modes	  of	  transmission	  will	  be	  
presented	  and	  used	  to	  better	  understand	  my	  main	  focus	  on	  perinatal	  infection	  prevention.	  Furthermore	  it	  
seems	  reasonable	  to	  touch	  upon	  the	  mechanism	  behind	  the	  hepatitis	  B	  vaccination	  and	  current	  routines	  
for	  diagnosis	  and	  staging	  of	  the	  disease.	  I	  would	  like	  to	  point	  out	  that	  the	  immunology	  presented	  is	  
simplified	  to	  avoid	  loosing	  track	  of	  the	  essentials	  of	  this	  assignment.	  The	  very	  important	  topic	  of	  co-­‐
infection	  with	  HIV	  is	  deliberately	  not	  presented,	  although	  this	  is	  highly	  problematic	  and	  a	  present	  issue.	  
Finally,	  my	  aim	  is	  to	  address	  to	  the	  major	  global	  health	  problems,	  not	  the	  minor	  and	  put	  the	  combat	  
against	  hepatitis	  B	  on	  the	  agenda	  in	  line	  with	  HIV,	  malaria	  and	  tuberculosis.	  
	  
3.	  Methodology	  and	  process	  
	   3.1	  Search	  strategy	  
	  
Studies	  and	  other	  relevant	  references	  for	  the	  assignment	  were	  identified	  through	  searches	  in	  electronic	  
databases	  and	  guidelines.	  I	  have	  used	  PubMed	  and	  Medline	  for	  articles	  mainly	  published	  from	  January	  
2014	  to	  get	  the	  latest	  research	  in	  a	  field	  of	  constant	  change.	  However,	  some	  of	  the	  literature	  used	  has	  
been	  published	  before	  2014.	  The	  search	  terms	  used	  in	  combination	  with	  hepatitis	  B	  were:	  “mother-­‐to-­‐
child	  transmission”,	  “perinatal	  transmission”,	  “pregnancy”,	  “vaccine”,	  “Vietnam”,	  Cambodia”,	  “neonatal”,	  
“child”.	  Other	  relevant	  articles	  were	  identified	  through	  searches	  in	  Google	  Scholar.	  Central	  articles	  has	  
also	  been	  looked	  up	  using	  Google	  Scholar	  to	  see	  other	  articles	  that	  has	  sited	  that	  particular	  article	  of	  
interest.	  Especially	  was	  this	  used	  to	  follow	  the	  development	  of	  research	  within	  one	  topic	  from	  a	  couple	  of	  
years	  back	  up	  to	  date.	  Scanning	  of	  reference	  lists	  of	  central	  articles	  has	  been	  used.	  Guidelines	  by	  WHO,	  
AASLD,	  EASL,	  APASL,	  CDC	  and	  FHI	  concerning	  hepatitis	  positive	  pregnant	  and	  children	  born	  to	  positive	  
mothers	  has	  carefully	  been	  read,	  but	  only	  some	  of	  the	  guidelines	  has	  been	  used	  in	  this	  assignment.	  
	   3.2	  Risk	  of	  bias	  
	  
As	  I	  started	  up	  with	  the	  research	  of	  this	  assignment	  I	  had	  a	  vision	  of	  how	  it	  would	  look	  like.	  My	  way	  of	  
finding	  literature	  could	  possible	  be	  affected	  by	  selection	  bias.	  However	  I	  have	  tried	  to	  find	  multiple,	  
independent,	  references	  to	  support	  the	  topics,	  especially	  where	  literature	  seems	  to	  not	  be	  in	  consensus.	  
The	  same	  was	  done	  with	  the	  guidelines,	  but	  as	  the	  extent	  of	  this	  assignment	  is	  limited,	  I	  have	  not	  included	  
them	  all.	  For	  most	  of	  the	  articles	  included	  the	  author	  declared	  no	  conflict	  of	  interest.	  I	  would	  like	  to	  point	  
out	  one	  of	  my	  experiences	  concerning	  newly	  published	  literature,	  which	  could	  be	  a	  weakness	  in	  this	  
assignment.	  It	  is	  easy	  to	  be	  blended	  by	  the	  date	  of	  publication,	  but	  the	  list	  of	  references	  is	  often	  built	  up	  
on	  studies	  from	  many	  years	  back,	  typically	  in	  reviews.	  This	  might	  have	  been	  the	  case	  in	  this	  assignment	  
as	  I	  have	  used	  a	  few	  reviews	  throughout.	  Publication	  bias	  might	  be	  a	  problem,	  as	  in	  all	  research,	  but	  my	  
searches	  has	  been	  as	  broad	  as	  possible	  and	  only	  using	  independent	  databases.	  The	  data	  upon	  vaccination	  
rates	  from	  WHO	  database	  is	  based	  on	  WHO/UNICEF	  estimates	  and	  not	  on	  official	  country	  estimates,	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neither	  on	  coverage	  surveys.	  Interestingly	  the	  official	  country	  estimates	  in	  Vietnam	  and	  Cambodia	  
concerning	  the	  birth	  dose	  are	  over	  all	  overestimated	  compared	  to	  WHO/UNICEF	  estimates.	  Looking	  at	  
the	  three-­‐dose	  vaccine,	  the	  data	  are	  identical.	  However,	  since	  the	  database	  is	  based	  on	  estimates	  and	  not	  
coverage	  surveys	  the	  risk	  of	  incorrect	  estimations	  are	  present.	  
	   3.3	  The	  process	  	  
	  
The	  description	  of	  the	  project	  was	  handed	  in	  according	  to	  guidelines	  given	  by	  the	  university,	  thus	  due	  to	  a	  
semester	  in	  Zimbabwe	  the	  hole	  processes	  was	  difficult	  to	  start	  before	  returning	  to	  Norway	  in	  December	  
2014.	  My	  plan	  was	  initially	  to	  focus	  on	  the	  transmission	  of	  hepatitis	  between	  mother	  and	  child	  in	  Vietnam	  
and	  Cambodia	  using	  national	  data	  upon	  vaccination	  coverage	  and	  seroprevalences.	  A	  shift	  of	  focus	  due	  to	  
difficulties	  with	  data	  access	  and	  the	  fact	  that	  these	  data	  do	  not	  exist,	  lead	  to	  a	  shift	  toward	  a	  global	  
perspective.	  However	  I	  have	  chosen	  to	  use	  Cambodia	  and	  Vietnam,	  two	  high	  endemic	  countries,	  to	  give	  
insight	  in	  recourse	  limited	  countries	  to	  better	  understand	  mother-­‐to-­‐child-­‐transmission.	  As	  a	  substitution	  
to	  national	  based	  data,	  I	  have	  chosen	  to	  use	  WHO	  databases,	  based	  on	  WHO/UNICEF	  estimates.	  With	  
these	  data	  I	  have	  made	  some	  basic	  figures	  demonstrating	  vaccination	  coverage	  the	  past	  years	  using	  Excel.	  
Moreover,	  the	  process	  has	  mainly	  been	  dependent	  on	  searches	  in	  literature	  and	  guidelines	  spring	  2016.	  
My	  supervisor,	  Tore	  Gutteberg,	  has	  always	  been	  available	  either	  on	  e-­‐mail	  or	  for	  meetings,	  which	  has	  
made	  the	  progress	  smooth.	  
	  
4.	  Introduction	  to	  the	  virus-­‐	  virology	  
	  
HBV	  virions	  are	  DNA	  double-­‐stranded	  enveloped	  virus	  [9],	  build	  up	  by	  an	  outer	  lipoprotein	  envelope	  
containing	  three	  glycoproteins	  (viral	  surface	  antigens).	  It	  contains	  a	  polymerase,	  which	  also	  serves	  as	  a	  
reverse	  transcriptase.	  HBsAg	  is	  one	  out	  of	  three	  glycoproteins	  attached	  to	  the	  envelope.	  	  Hepatitis	  B	  core	  
antigen	  (HBcAg)	  is	  among	  others	  important	  in	  regulation	  of	  replication	  [16],	  and	  HBeAg	  is	  described	  to	  
play	  a	  role	  in	  modulating	  the	  host	  immune	  response	  [17].	  A	  liver	  bile	  acid	  transporter,	  sodium-­‐
taurocholate	  co-­‐transporting	  polypeptide	  (NTCP),	  was	  newly	  discovered	  as	  the	  target	  for	  HBV	  to	  bind	  to	  
the	  hepatocyte	  [18].	  Subsequently,	  HBV	  enters	  the	  hepatocytes	  through	  either	  endocytosis	  or	  fusion	  with	  
the	  viral	  lipoprotein	  envelope	  to	  the	  plasma	  membrane	  [19].	  Furthermore,	  the	  core	  particles	  of	  the	  virus	  
enters	  the	  nucleus	  where	  covalently	  closed	  circular	  DNA	  (cccDNA)	  is	  formed,	  figure	  1	  [16].	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Figure	  1.	  	  Lifecycle	  of	  HBV	  using	  a	  hepatocyte	  as	  host.	  The	  cycle	  includes	  viral	  entry,	  integration	  and	  
cccDNA	  formation,	  viral	  transcription	  into	  mRNA	  and	  translation.	  Moreover	  the	  cycle	  is	  completed	  by	  
virion	  secretion	  or	  the	  secretion	  of	  viral	  proteins,	  such	  as	  HBeAg	  and	  HBsAg,	  that	  can	  be	  detected	  in	  blood	  
[16,	  19].	  
	  
HBV	  causes	  liver	  injury	  through	  immune-­‐mediated	  killing	  of	  the	  hepatocyte	  and	  is	  also	  an	  oncogenic	  virus	  
[20].	  There	  are	  multiple	  viral	  genotypes	  and	  serotypes	  that	  have	  been	  identified.	  Each	  with	  a	  different	  
geographically	  prevalence	  [16].	  In	  total,	  it	  is	  identified	  eight	  HBV	  genotypes	  (A-­‐H)	  and	  two	  temporary	  (I,	  
J).	  Although	  the	  mechanism	  is	  not	  fully	  understood,	  these	  genotypes	  show	  differences	  in	  disease	  severity/	  
outcome	  of	  infection	  [9,	  21].	  Allelic	  dominance	  in	  genetic	  polymorphism	  in	  human	  leukocyte	  antigen	  
(HLA)	  class	  II	  and	  nuclear	  factor-­‐kappaB	  (NF-­‐kB)	  may	  explain	  why	  people	  from	  East	  Asia	  more	  easily	  
develop	  a	  chronic	  infection	  than	  in	  the	  European	  population	  [13],	  moreover	  genotype	  C	  and	  B	  is	  endemic	  
in	  East	  Asia	  while	  E	  and	  D	  are	  more	  prevalent	  in	  Europe	  [22].	  	  A	  higher	  rate	  of	  hepatocellular	  carcinoma	  
(HCC)	  has	  been	  found	  in	  persons	  infected	  with	  genotypes	  C	  and	  F	  [20],	  and	  HBV	  genotype	  C	  is	  more	  
rarely	  cleared	  by	  antiviral	  immunity	  than	  genotype	  B	  [13].	  	  HBV	  has	  a	  high	  rate	  of	  replication	  and	  is	  as	  a	  
consequence	  to	  this	  prone	  to	  undergo	  genetic	  mutations	  [20].	  
	  
An	  infection	  with	  the	  hepatitis	  B	  virus	  can	  either	  be	  acute	  or	  chronic,	  and	  has	  a	  great	  variety	  of	  
presentations.	  Clinically,	  individuals	  that	  undergoes	  an	  infection	  can	  be	  asymptomatic	  or	  have	  mild	  
disease	  to	  a	  serious,	  and	  fulminant	  hepatitis	  [20].	  	  	  
4.1	  Acute	  hepatitis	  B	  virus	  infection:	  focus	  on	  pregnant	  and	  children	  
	  
The	  acute	  phase	  of	  the	  infection	  is	  often	  self-­‐limiting	  and	  characterized	  by	  acute	  inflammation	  and	  
hepatocellular	  necrosis.	  Clinically	  it	  presents	  with	  different	  signs	  and	  symptoms,	  including	  nonspecific	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symptoms	  such	  as	  anorexia,	  nausea	  or	  malaise	  and	  clinical	  hepatitis	  with	  jaundice.	  Of	  individuals	  
undergoing	  an	  acute	  infection	  0.5-­‐1%	  is	  thought	  to	  die	  from	  a	  fulminant	  hepatitis	  (case	  fatality	  rate)	  [20].	  	  
Worth	  mentioning	  is	  that	  children	  do	  have	  less	  chance	  of	  an	  clinical	  acute	  HBV	  infection,	  they	  often	  
present	  as	  asymptomatic,	  while	  adult	  have	  about	  30%	  chance	  of	  developing	  symptoms	  [23].	  Acute	  HBV	  
infection	  is	  serological	  characterized	  by	  the	  presence	  of	  HBsAg	  and	  Immunglobulin	  M	  (IgM)	  antibody	  to	  
the	  hepatitis	  B	  core	  antigen	  (HBcAg).	  In	  the	  initial	  phase,	  the	  individual	  is	  also	  HBeAg	  positive,	  figure	  2	  
[1].	  Recovery,	  without	  progression	  to	  a	  chronic	  infection,	  is	  characterized	  by	  the	  disappearance	  of	  HBsAg	  




Figure	  2.	  	  Typical	  serologic	  course	  of	  acute	  HBV	  infection	  with	  progression	  to	  chronic	  HBV	  infection	  [24].	  
	  
A	  pregnant	  woman	  that	  undergoes	  an	  acute	  HBV	  infection	  mostly	  undergoes	  the	  same	  course	  as	  
individuals	  in	  the	  general	  adult	  population.	  However,	  the	  risk	  of	  intrauterine	  transmission	  and	  preterm	  
labour	  increases	  the	  later	  in	  gestation	  the	  infection	  occurs	  [9,	  25].	  Another	  important	  factor	  is	  the	  levels	  
of	  viremia	  that	  the	  mother	  have	  in	  pregnancy.	  High	  levels	  of	  viremia	  increases	  the	  risk	  of	  vertical	  
transmission,	  this	  will	  be	  discussed	  further	  below	  [25].	  It	  is	  critical	  to	  differentiate	  between	  pregnancy	  
associated	  acute	  liver	  disease	  and	  acute	  viral	  hepatitis.	  Pregnancy	  associated	  acute	  liver	  diseases	  includes	  
preeclampsia,	  acute	  fatty	  liver	  of	  pregnancy	  and	  haemolysis	  elevated	  liver	  enzymes	  and	  low	  platelet	  
syndrome	  (HELLP).	  The	  distinction	  of	  these	  states	  of	  disease	  and	  acute	  viral	  hepatitis	  is	  often	  difficult	  
based	  on	  clinical	  signs	  and	  symptoms	  or	  nonspecific	  laboratory	  findings	  [26].	  
4.2	  Chronic	  hepatitis	  B	  infection:	  focus	  on	  pregnant	  and	  children	  
	  
A	  CHB	  infection	  is	  characterized	  and	  defined	  by	  the	  presence	  of	  detectable	  HBsAg	  (with	  or	  without	  
coexisting	  HBeAg)	  in	  the	  blood	  or	  serum	  for	  more	  than	  six	  months.	  Regardless	  of	  associated	  active	  viral	  
replication	  and	  proof	  of	  hepatocellular	  injury	  and	  inflammation,	  this	  is	  called	  a	  persistent	  HBV	  infection	  




CHB	  includes	  a	  range	  of	  different	  presentations	  from	  inactive,	  leading	  to	  no	  significant	  liver	  disease,	  to	  
gradually	  liver	  fibrosis	  and	  the	  development	  of	  liver	  cirrhosis	  [20].	  	  HBV	  and	  hepatitis	  C	  virus	  (HCV)	  
infection	  promote	  end-­‐	  stage	  liver	  disease	  and	  liver	  cirrhosis	  and	  is	  found	  in	  80-­‐90%	  of	  patients	  with	  
HCC.	  Replication	  state	  of	  the	  virus	  (HBV	  DNA	  levels),	  HBV	  genotype,	  duration	  of	  infection	  and	  co-­‐
infections	  with	  HCV	  or	  HIV	  are	  all	  factors	  that	  are	  reported	  to	  increase	  the	  risk	  of	  HCC.	  HCC	  is	  the	  most	  
common	  form	  of	  liver	  cancer	  [27]	  and	  poses	  a	  great	  health	  problem	  on	  the	  individual	  patient	  as	  well	  as	  a	  
socioeconomic	  burden,	  affecting	  less	  developed	  countries	  to	  a	  greater	  extend	  [11,	  28].	  	  
	  
As	  pointed	  out	  in	  the	  introduction,	  age	  at	  time	  of	  infection	  is	  a	  critical	  factor	  and	  determinant	  in	  regards	  
to	  the	  risk	  of	  processing	  to	  a	  chronic	  infection.	  The	  risk	  of	  obtaining	  CHB	  is	  inversely	  propositional	  with	  




Figure	  3.	  The	  risk	  of	  developing	  a	  CHB	  infection	  is	  inversely	  propositional	  with	  age	  of	  exposure,	  giving	  
transmission	  at	  birth	  the	  greatest	  risk.	  As	  described	  in	  the	  figure,	  this	  group	  also	  have	  the	  fewest	  
symptoms	  of	  an	  infection	  [20].	  
	  
It	  was	  previous	  consensus	  that	  neonates	  established	  CHB	  because	  of	  the	  immaturity	  of	  their	  immune	  
system.	  However,	  new	  research	  indicates	  that	  the	  immune	  system	  of	  neonates	  is	  efficient	  enough	  to	  
respond	  immunologically.	  An	  individual	  that	  is	  infected	  perinatally	  will	  typically	  have	  a	  normal	  serum	  
alanine	  aminotransferase	  (ALT)	  level,	  positive	  HBeAg,	  high	  HBV	  DNA	  levels	  and	  little	  liver	  inflammation	  
[16].	  This	  phase	  is	  now	  called	  “high	  replicative,	  low	  inflammatory”	  phase	  (first	  out	  of	  five	  phases)	  and	  can	  
sustain	  many	  years	  without	  development	  [29],	  see	  figure	  4.	  Mechanisms	  of	  transmission	  of	  HBV	  will	  be	  
discussed	  below	  and	  the	  major	  route	  of	  transmission	  varies	  between	  continents.	  In	  more	  developed	  
countries,	  where	  the	  prevalence	  is	  low,	  HBV	  infection	  typically	  occurs	  in	  adults	  and	  rather	  through	  sexual	  
exposure	  or	  injection	  drug	  use,	  which	  leads	  to	  an	  immediate	  entry	  into	  the	  “immune	  clearance	  phase”	  (2nd	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phase).	  Figure	  4	  includes	  all	  the	  five	  phases	  of	  CHB	  infection	  with	  an	  acute	  HBV	  infection	  as	  a	  starting	  
point.	  However,	  it	  is	  pointed	  out	  in	  literature	  that	  these	  stages	  are	  not	  static,	  not	  always	  sequential,	  and	  
not	  all	  patients	  go	  through	  all	  five	  phases	  [16,	  30].	  Table	  1	  summarizes	  all	  five	  phases	  of	  a	  chronic	  
hepatitis	  B	  virus	  infection	  [16].	  	  
	  
	  
Figure	  4.	  Five	  major	  phases	  of	  chronic	  hepatitis	  B	  virus	  infection.	  Perinatal	  transmission	  often	  results	  in	  
“high-­‐replicative,	  low-­‐inflammatory”	  infection,	  phase	  1	  (previously	  called	  “immune	  tolerant”).	  
Transmission	  in	  childhood	  commonly	  leads	  to	  HBeAg	  negative	  (-­‐)	  chronic	  hepatitis,	  characterized	  by	  
persistent	  necroinflammation	  (phase	  3),	  while	  adult	  infection	  commonly	  leads	  to	  immune	  clearance	  
(phase	  2)	  or	  “HBsAg	  loss”/”occult	  HBV”	  (phase	  5),	  also	  called	  resolution	  phase.	  Phase	  4,	  non-­‐replicative,	  
was	  previously	  called	  “inactive	  carrier”	  with	  low/undetectable	  serum	  HBV	  DNA,	  very	  low	  HBsAg	  levels,	  
HBeAg(-­‐)	  status,	  and	  normal	  ALT	  [16].	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   4.3	  Immune	  escape	  in	  CHB-­‐	  why	  are	  infected	  neonates	  more	  prone	  to	  develop	  CHB?	  
	  
As	  mention	  previously,	  HBV	  still	  exists	  in	  a	  large	  part	  of	  the	  human	  population.	  The	  virus	  is	  efficient	  in	  
coexisting	  with	  its	  host.	  Before	  going	  further	  into	  the	  topic	  it	  is	  worth	  mentioning	  that	  the	  consequences	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of	  a	  vertical	  transmission	  of	  HBV	  is	  still	  not	  fully	  understood.	  Literature	  also	  points	  out	  that	  the	  
difficulties	  and	  limitations	  in	  studies,	  of	  the	  establishment	  of	  a	  chronic	  HBV	  infection,	  are	  among	  others	  
due	  to	  the	  guidelines	  of	  vaccination	  of	  neonates	  within	  24	  hours	  after	  birth.	  Looking	  at	  the	  general	  picture	  
in	  the	  combat	  of	  infections,	  infants	  are	  more	  vulnerable	  to	  severe	  infections	  as	  a	  consequence	  of	  
functional	  differences	  in	  their	  immune	  system.	  	  The	  development	  into	  a	  persistent	  HBV	  infection	  has	  
previously	  been	  recognized	  as	  a	  consequence	  of	  this	  immaturity.	  However	  there	  is	  an	  increased	  
recognition	  that	  the	  neonatal	  immune	  system	  is	  not	  defective.	  The	  term	  “trained	  immunity”	  in	  newborns	  
has	  been	  used	  as	  an	  example	  to	  support	  this	  theory.	  Trained	  immunity	  is	  the	  induction	  of	  the	  innate	  	  
(complement,	  phagocytes,	  natural	  killer	  cells)	  immune	  system,	  which	  has	  been	  successfully	  achieved	  in	  
vivo,	  but	  also	  seen	  in	  utero	  [29].	  
	  
Looking	  at	  adults,	  they	  are	  in	  most	  cases	  able	  to	  spontaneously	  “clear”	  the	  virus	  from	  the	  blood	  after	  an	  
acute	  infection,	  as	  descried	  above	  in	  phase	  5.	  However	  they	  often	  maintain	  a	  low	  level	  of	  infection	  
throughout	  their	  lives,	  so	  called	  an	  occult	  infection.	  It	  was	  previously	  thought	  that	  these	  people	  was	  free	  
from	  the	  virus,	  this	  is	  however	  not	  entirely	  true	  as	  the	  virus	  persists	  in	  the	  hepatocytes	  [31].	  	  For	  the	  
virus	  to	  become	  chronic	  and	  prevent	  clearance,	  it	  is	  dependent	  on	  modifying	  the	  host	  immune	  response.	  
The	  virus	  has	  developed	  mechanisms	  to	  counteract	  and	  escape	  different	  host	  response	  [30].	  	  The	  host	  
innate	  and	  adaptive	  (antigenpresenting	  cells,	  B-­‐	  and	  T-­‐cells)	  immune	  response	  itself	  is	  also	  thought	  to	  be	  
contributors	  to	  the	  formation	  of	  fibrosis,	  and	  risk	  of	  developing	  HCC	  [16,	  31].	  As	  literature	  points	  out,	  
much	  has	  been	  learned	  about	  the	  HBV-­‐specific	  adaptive	  immunity,	  but	  early	  innate	  host	  immune	  
response	  during	  an	  acute	  infection	  is	  still	  in	  general	  unknown	  [30,	  32].	  Some	  literature	  speculate	  that	  
HBeAg	  might	  establish	  chronic	  HBV	  infection	  through	  induction	  of	  T-­‐cell	  tolerance	  to	  HBV	  in	  utero	  [33].	  
Various	  factors	  influence	  on	  the	  timing	  of	  HBeAg	  seroconversion,	  including	  age,	  genotype	  and	  age	  at	  
acquisition	  of	  virus.	  In	  perinatally	  infected	  Asians,	  it	  is	  seen	  a	  prolonged	  period	  of	  immune	  tolerance	  and	  
low	  rate	  of	  clearance	  of	  HBeAg	  until	  later	  life	  [13,	  34].	  A	  study	  published	  in	  2015	  upon	  trained	  immunity	  
poses	  two	  possible	  theories,	  either	  is	  the	  development	  into	  CHB	  in	  neonates	  associated	  with	  a	  strong	  Th1-­‐
cell	  response,	  or	  it	  may	  be	  related	  to	  defects	  in	  priming	  of	  adaptive	  immunity,	  as	  seen	  in	  studies	  with	  
animals	  [29].	  
	  
5.	  MTCT	  of	  HBV:	  Mechanisms	  and	  influencing	  factors	  
	  
As	  briefly	  described	  in	  previous	  sections,	  modes	  of	  transmission	  vary	  depending	  on	  the	  endemicity	  of	  the	  
virus.	  In	  highly	  endemic	  areas,	  such	  as	  South-­‐East	  Asia,	  the	  major	  route	  of	  transmission	  is	  perinatally	  or	  
in	  early	  childhood	  [12].	  Even	  in	  areas	  with	  low	  endemicity	  one	  third	  of	  the	  cases	  of	  chronic	  infection	  
happens	  as	  a	  consequence	  of	  transmission	  during	  the	  perinatal	  period	  or	  early	  childhood	  [14].	  This	  
assignment	  will	  not	  look	  further	  into	  horizontal	  transmission,	  but	  it	  is	  worth	  mentioning	  that	  the	  HBV	  is	  
transmitted	  through	  percutaneous	  and	  mucosal	  contact,	  with	  blood	  or	  body	  fluids,	  and	  can	  persist	  viable	  
for	  several	  days	  in	  the	  environment	  [1,	  9].	  However	  understanding	  the	  mechanisms	  of	  MTCT	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transmission	  is	  essential	  when	  trying	  to	  understand	  the	  different	  prevention	  strategies	  that	  will	  be	  
described	  below.	  Literature	  divides	  MTCT	  into	  three	  possible	  routes	  [12].	  
5.1	  Intrauterine	  transmission	  
	  
Intrauterine	  transmission	  occurs	  while	  the	  foetus	  is	  still	  in	  the	  uterus.	  There	  is	  not	  yet	  fully	  consensus	  
about	  the	  mechanisms,	  but	  there	  are	  several	  hypotheses.	  Transmission	  of	  serum/body	  fluid,	  as	  a	  
consequence	  of	  placenta	  damage,	  is	  one	  of	  the	  most	  frequently	  mentioned.	  Other	  routes	  described	  are	  
due	  to	  invasive	  procedures	  into	  uterus,	  such	  as	  amniocentesis.	  Specific	  infections	  with	  Toxoplasmosis,	  
Rubella,	  Cytomegalovirus	  and	  Herpes	  Simplex	  (TORCH)	  are	  also	  pointed	  out	  as	  possible	  co-­‐factors	  [7,	  12].	  
Genetic	  transmission	  [7,	  12]	  and	  transmission	  at	  the	  level	  of	  spermcell	  and	  oocytes	  that	  can	  be	  infected	  
and	  transfer	  the	  HBV	  to	  the	  embryo,	  has	  also	  been	  suggested	  [35].	  
	  
Intrauterine	  transmission	  is	  considered	  to	  be	  the	  main	  route	  of	  the	  three	  possible	  MTCT	  as	  a	  consequence	  
of	  treatment	  failure,	  which	  will	  be	  discussed	  below	  [12,	  36].	  The	  risk	  of	  intrauterine	  transmission	  
increases	  with	  higher	  levels	  of	  HBV	  DNA	  in	  serum	  and	  HBeAg	  positive	  status	  in	  the	  mother	  [37,	  38].	  
5.2	  Intrapartum	  transmission	  	  
	  
Intrapartum	  transmission	  includes	  natal	  transmission	  during	  delivery	  [7,	  12].	  This	  route	  of	  transmission	  
is	  said	  to	  be	  the	  major	  route	  responsible	  for	  perinatal	  transmission	  [12].	  During	  childbirth	  the	  newborns	  
pass	  through	  the	  genital	  tract	  and	  may	  be	  exposed	  to	  maternal	  body	  fluids	  or	  blood	  [33].	  Strong	  uterine	  
contractions	  during	  birth	  can	  also	  lead	  to	  damage	  of	  the	  placenta	  villi	  vessels	  and	  leakage	  of	  maternal	  
blood	  into	  the	  foetal	  circulation.	  Factors	  such	  as	  mode	  of	  delivery	  and	  length	  of	  labour	  could	  in	  theory	  
influence	  the	  transmission,	  but	  is	  controversial	  [7].	  Most	  studies	  find	  no	  significant	  difference	  in	  MTCT	  
between	  children	  born	  with	  elective	  caesarean	  section	  and	  vaginal	  deliveries,	  thus	  caesarean	  delivery	  is	  
not	  recommended	  in	  HBsAg-­‐positive	  mothers.	  However,	  procedures	  such	  as	  foetal	  scalp	  electrode	  
insertion,	  or	  instrumental	  delivery	  should	  be	  avoided	  in	  HBV-­‐carrying	  mothers	  [9].	  
An	  indirect	  cause	  of	  MTCT	  is	  described	  in	  literature	  as	  compliance	  of	  birth	  dose	  of	  HBV	  vaccine	  as	  a	  
consequence	  of	  out-­‐of-­‐hospital	  births,	  these	  factors	  will	  be	  discussed	  below	  [39].	  
5.3	  Puerperal	  transmission	  
	  
This	  route	  is	  more	  commonly	  called	  postpartum	  transmission.	  The	  transmission	  occurs	  during	  care	  with	  
exposure	  to	  maternal	  body	  fluid	  or	  blood,	  or	  through	  breast	  milk	  and	  represents	  a	  less	  common	  way	  of	  
MTCT	  [7,	  12].	  It	  is	  more	  or	  less	  consensus	  in	  literature	  that	  breastfeeding	  after	  injection	  of	  hepatitis	  B	  
immunoglobulin	  (HBIG)	  does	  not	  contribute	  to	  MTCT	  of	  HBV.	  However	  some	  of	  these	  studies	  do	  not	  
include	  maternal	  HBV	  DNA	  levels	  [9,	  40].	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6.	  Diagnosis	  and	  staging	  
	  
HBsAg	  is	  the	  standard	  diagnostic	  marker	  used	  to	  screen	  for	  in	  pregnant	  women.	  A	  positive	  test	  indicates	  
an	  acute	  or	  chronic	  infection.	  HBeAg	  indicates	  that	  the	  virus	  is	  actively	  replicating	  and	  typically	  correlates	  
with	  higher	  levels	  of	  HBV	  DNA.	  IgG	  and	  IgM	  to	  HBcAg	  indicates	  either	  that	  the	  individual	  has	  previously	  
been	  infected	  or	  has	  an	  ongoing	  infection.	  IgG	  anti	  hepatitis	  B	  core	  (IgG	  anti-­‐HBc)	  will	  typically	  persists	  
for	  life.	  Detection	  of	  anti-­‐HBs	  indicates	  that	  the	  individual	  has	  obtained	  immunity	  either	  from	  infection	  or	  
vaccination.	  Table	  2	  summarizes	  the	  diagnostic	  testes	  for	  HBV	  antigens	  and	  antibodies	  [31,	  41],	  table	  3	  
gives	  an	  overview	  of	  serological	  markers	  for	  hepatitis	  B	  and	  possible	  status	  of	  the	  individual	  [31].	  
	  	  
Table	  2.	  Diagnostic	  tests	  for	  hepatitis	  B	  virus	  antigens	  and	  antibodies	  including	  field	  of	  use.	  
Factors	  to	  be	  tested	   HBV	  antigen	  or	  
antibody	  
Use	  
HBsAg	   Hepatitis	  B	  surface	  
antigen	  
Detection	  of	  acutely	  or	  chronically	  infected	  people;	  antigen	  used	  in	  
hepatitis	  B	  vaccine;	  can	  be	  detected	  for	  up	  to	  a	  month	  after	  a	  dose	  
of	  hepatitis	  B	  vaccine	  
HBeAg	   Hepatitis	  B	  e	  antigen	   Identification	  of	  infected	  people	  at	  increased	  risk	  (active	  
replication	  of	  virus)	  of	  transmitting	  HBV	  
Anti-­‐HBs	   Antibody	  to	  HBsAg	   Identification	  of	  people	  who	  have	  resolved	  infections	  
with	  HBV;	  determination	  of	  immunity	  after	  immunization	  
Anti-­‐HBe	   Antibody	  to	  HBeAg	   Identification	  of	  infected	  people	  with	  lower	  risk	  of	  transmitting	  
HBV	  
Anti-­‐HBc	  (total)	   Antibody	  to	  HBcAga	   Identification	  of	  people	  with	  acute,	  resolved,	  or	  chronic	  HBV	  
infection	  (not	  present	  after	  immunization);	  passively	  transferred	  
maternal	  anti-­‐HBc	  is	  detectable	  for	  as	  long	  as	  24	  months	  among	  
infants	  born	  to	  HBsAg-­‐positive	  women	  
IgM	  anti-­‐HBc	   IgM	  antibody	  to	  HBcAg	   Identification	  of	  people	  with	  acute	  or	  recent	  HBV	  
infections	  (including	  HBsAg-­‐negative	  people	  
during	  the	  “window”	  phase	  of	  infection;	  unreliable	  
for	  detecting	  perinatal	  HBV	  infection)	  
HBV	  DNA	   	   HBV	  DNA	  correlates	  with	  levels	  of	  circulating	  viral	  particles	  in	  
blood	  and	  is	  an	  important	  marker	  to	  evaluate	  the	  clinical	  
progression,	  e.g.	  evaluate	  the	  effect	  of	  antiviral	  treatment.	  HBV	  
DNA	  is	  measured	  as	  IU/mL	  
	  
Table	  3.	  Overview	  of	  serological	  markers	  for	  hepatitis	  B	  and	  possible	  hepatitis	  B-­‐status.	  
	   HBsAg	   Anti-­‐HBs	   Anti-­‐HBc	  IgM	   Anti-­‐HBc	  
Susceptible	  to	  infection	   Negative	   Negative	   Negative	   Negative	  
Acute	  infection	   Positive	   Negative	   Positive	   Positive	  
Chronic	  infection	  (carrier)	   Positive	   Negative	   Negative	   Positive	  
Chronic	  active	  infection	   Positive	   Negative	   Positive/	  Negative	   Positive	  
Immunity	  after	  infection	   Negative	   Positive	  	   Negative	   Positive	  
Immunity	  after	  vaccine	   Negative	   Positive	   Negative	   Negative	  
Uncertain	  status*	   Negative	   Negative	   Negative	   Positive	  
*Could	  indicate	  previous	  infection	  and	  immunity,	  low	  grade	  of	  CHB	  infection	  or	  a	  late	  phase	  in	  an	  acute	  infection.	  
	  
Touching	  upon	  the	  technical	  procedures	  behind	  the	  tests,	  HBV	  serological	  markers	  are	  detected	  by	  
different	  techniques,	  dependent	  on	  available	  resources.	  In	  a	  setting	  with	  few	  economic	  limitations,	  as	  in	  
Norway,	  Chemiluminescent	  Microparticle	  Immunoassay	  (CMIA)	  is	  used	  to	  qualitatively	  prove	  hepatitis	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antigen	  in	  blood	  or	  serum.	  The	  technique	  has	  a	  high	  specificity	  and	  sensitivity	  and	  is	  based	  on	  the	  
characteristics	  of	  antigens	  (e.g.	  HBsAg	  or	  HBeAg)	  binding	  to	  commercially	  produced	  antibodies	  (anti-­‐HB)	  
with	  chemiluminescents	  [42,	  43].	  The	  light	  produced	  in	  a	  chemiluminescent	  reaction	  is	  measured.	  This	  
technique	  is	  more	  sensitive	  than	  the	  former	  used	  enzyme	  Linked	  Immunosorbent	  Assay	  (ELISA)	  [43].	  
HBV	  cccDNA	  are	  detected	  by	  real-­‐time	  polymerase	  chain	  reaction	  (PCR)	  [20].	  PCR	  can	  in	  short	  be	  
described	  as	  a	  nucleic	  acid	  amplification	  technique	  that	  binds	  to	  the	  HBV	  DNA	  and	  greatly	  increase	  the	  
amount	  of	  DNA.	  This	  technique	  can	  qualitatively	  or	  quantitatively	  detect	  the	  amount	  of	  HBV	  DNA	  in	  the	  
sample,	  which	  reflects	  the	  replicative	  state	  of	  the	  virus.	  For	  monitoring	  a	  HBV	  infection,	  the	  quantitative	  
detection	  is	  very	  important,	  as	  described	  further	  below	  [43].	  ALT	  levels	  are	  measured	  to	  help	  determine	  
liver	  inflammation.	  ALT	  is	  an	  enzyme,	  commonly	  found	  in	  the	  liver,	  but	  also	  present	  in	  various	  body	  
tissue,	  that	  is	  released	  into	  the	  circulation	  system	  as	  a	  consequence	  to	  hepatocellular	  injury	  [44].	  
Together	  with	  HBV	  DNA,	  ALT	  is	  important	  to	  characterize	  the	  phase	  of	  infection	  [45].	  Several	  non-­‐
invasive	  tests	  such	  as	  aspartate	  aminotransferase	  (AST)-­‐to-­‐platelet	  ratio	  index	  (APRI)	  and	  transient	  
elastography	  (FibroScan)	  exist.	  APRI	  is	  an	  index	  to	  estimate	  hepatic	  fibrosis	  based	  on	  a	  formula	  derived	  
from	  AST	  and	  platelet	  concentrations.	  FibroScan	  is	  a	  technique	  to	  measure	  grade	  of	  liver	  fibroses	  through	  
the	  detection	  of	  liver	  stiffness.	  Both	  techniques	  are	  recommended	  by	  WHO	  to	  assess	  for	  the	  presence	  of	  
cirrhosis,	  but	  while	  FibroScan	  is	  preferred	  in	  a	  context	  where	  availability	  and	  cost	  is	  not	  an	  issue,	  APRI	  is	  
used	  in	  resource-­‐limited	  settings.	  Liver	  biopsy	  has	  been	  used	  to	  determine	  the	  degree	  of	  fibrosis	  and	  
necroinflammation,	  however	  the	  technique	  has	  multiple	  disadvantages	  and	  limitations,	  and	  will	  not	  be	  
discussed	  further	  in	  this	  assignment	  [20].	  
	  
Looking	  at	  the	  diagnostic	  part	  from	  a	  global	  health	  perspective	  the	  need	  for	  reliable,	  cost	  effective,	  rapid	  
tests	  to	  detect	  HBsAg,	  HBeAg	  and	  antibodies	  is	  obviously	  present	  [8].	  	  Not	  all	  current	  tests	  on	  the	  marked	  
are	  quality	  checked,	  and	  there	  are	  several	  problems	  that	  are	  pointed	  out	  to	  hinder	  the	  implementation	  of	  
screening	  programs.	  Among	  some,	  the	  need	  for	  sophisticated	  laboratory	  facilities,	  amount	  of	  blood	  
sample	  and	  the	  limitations	  in	  screening	  a	  general	  population,	  rather	  than	  detection	  of	  subgroups,	  such	  as	  
individuals	  in	  the	  immune-­‐tolerant	  phase	  [46].	  
	  
7.	  Monovalent	  HBV	  vaccine	  and	  hepatitis	  B	  immunoglobulin	  
	  
A	  prophylactic	  hepatitis	  B	  vaccine	  from	  serum	  was	  introduced	  in	  1983.	  It	  is	  estimated	  to	  give	  protection	  
in	  90-­‐95%	  of	  the	  cases	  [31].	  In	  contrast,	  there	  are	  no	  current	  prophylactic	  vaccine	  against	  the	  HCV,	  a	  RNA	  
virus,	  mainly	  due	  to	  the	  high	  viral	  replication	  and	  mutation	  rate	  [47].	  The	  HBV	  vaccine	  contains	  parts	  of	  
the	  hepatitis	  B	  virus	  produced	  in	  yeast	  cells	  with	  the	  aid	  of	  DNA	  technology.	  There	  are	  few	  reported	  side	  
effect	  concerning	  the	  vaccine.	  The	  most	  common	  reported	  are	  tenderness,	  redness	  and	  swelling	  at	  the	  
injection	  site.	  Fever,	  rash,	  weakness	  and	  aching	  joints	  and	  muscles	  in	  the	  following	  days	  are	  less	  common,	  
but	  reported	  [48].	  The	  vaccine	  comes	  as	  monovalent,	  meaning	  production	  of	  one	  virus	  type,	  and	  
pentavalent	  preparation,	  together	  with	  diphtheria,	  pertussis,	  tetanus	  and	  haemophilius	  influenza.	  This	  is	  
cost-­‐effective	  compared	  to	  the	  monovalent	  preparation	  and	  is	  frequently	  used	  in	  Africa	  and	  East	  Asia.	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However,	  the	  pentavalent	  is	  obviously	  not	  for	  use	  in	  newborn	  babies,	  thus	  can	  not	  be	  given	  as	  a	  birth	  
dose.	  The	  Vaccine	  Alliance	  (GAVI)	  no	  longer	  supports	  the	  monovalent	  vaccine	  with	  the	  consequences	  
following	  that	  [8].	  
	  
Passive	  immunization	  with	  HBIG	  gives	  a	  temporary	  immunity	  administrated	  as	  post-­‐exposure	  
prophylaxis	  through	  a	  short-­‐term	  increase	  in	  anti-­‐HBs.	  The	  combination	  of	  a	  vaccine	  and	  HBIG	  should	  be	  
giving	  right	  after	  birth,	  within	  24	  hours	  [20],	  although	  the	  benefits	  of	  HBIG	  is	  less	  clear	  among	  full-­‐term	  
neonates	  of	  HBsAg-­‐positive,	  but	  HBeAg-­‐negative	  mothers	  [9].	  Literature	  even	  declare	  no	  significantly	  
improved	  protection	  by	  the	  addition	  of	  HBIG	  [20].	  	  Due	  to	  HBIG	  storage	  criteria’s	  and	  complex	  production	  
it	  is	  an	  expensive	  procedure	  [8].	  
	   7.1	  Follow-­‐up	  after	  vaccination	  
	  
According	  to	  the	  Norwegian	  Institute	  of	  Public	  Health	  it’s	  among	  researchers	  an	  agreement	  that	  routine	  
testing	  of	  immunological	  healthy	  individuals,	  that	  have	  completed	  vaccination	  according	  to	  guidelines,	  is	  
not	  recommended.	  	  This	  is	  as	  a	  consequence	  of	  an	  expected	  96%	  protection	  with	  antibodies	  after	  fulfilling	  
the	  vaccination	  guidelines	  [31].	  Looking	  at	  the	  newly	  published	  “Alaska	  study”,	  a	  30	  years	  follow-­‐up	  
study,	  >94%	  had	  evidence	  of	  protection	  [49].	  However,	  Norwegian	  authorities	  recommended	  to	  control	  
the	  levels	  of	  anti-­‐HBs	  1-­‐3	  month	  after	  last	  dose	  is	  given	  to	  some	  specific	  groups,	  such	  as	  newborns	  to	  
HBsAg-­‐positive	  mothers.	  Testing	  for	  anti-­‐HBs	  after	  3	  months	  is	  regarded	  as	  inadequate,	  as	  the	  levels	  of	  
anti-­‐HBs	  level	  will	  decline	  over	  time,	  and	  will	  not	  indicate	  whether	  the	  individual	  has	  effect	  of	  the	  
vaccination	  or	  has	  accomplished	  long-­‐term	  protection.	  	  According	  to	  Norwegian	  guidelines	  from	  2015,	  a	  
booster	  dose	  is	  recommended	  in	  those	  with	  an	  antibody	  response	  <	  100	  IU/l	  after	  1-­‐3	  months	  [31].	  CDC	  
guidelines	  are	  more	  or	  less	  similar	  to	  Norwegians,	  but	  recommends	  post-­‐vaccination	  testing	  1-­‐2	  months	  
after	  completion	  of	  the	  final	  dose	  [50].	  
	  	  
8.	  	  Strategies	  for	  preventing	  MTCT	  of	  HBV	  
	  
Currently	  there	  is	  no	  curative	  treatment	  against	  a	  HBV	  infection.	  Oral	  treatment	  with	  antiviral	  drugs	  
suppresses	  the	  replication	  of	  the	  virus	  and	  slows	  the	  progression	  of	  liver	  complications.	  In	  the	  absence	  of	  
a	  cure,	  prevention	  strategies	  are	  highly	  prioritized	  [20].	  Preventive	  strategies	  of	  MTCT	  of	  HBV	  reach	  over	  
different	  levels,	  from	  medication	  during	  pregnancy	  and	  delivery,	  to	  postpartum	  strategies.	  It	  involves	  
among	  others	  screening	  of	  pregnant	  women,	  providing	  antiviral	  therapy	  to	  women	  with	  high	  HBV	  DNA	  
levels	  and	  administering	  passive-­‐active	  immunization	  to	  newborns	  of	  mothers	  who	  are	  HBsAg-­‐positive.	  
The	  integration	  of	  new	  findings	  in	  trials	  into	  national	  and	  international	  guidelines	  is	  a	  constant	  process.	  
	  
8.1	  Current	  strategy	  of	  post	  exposure	  prophylaxis	  (PEP).	  Recommendations	  by	  WHO	  and	  CDC	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The	  hepatitis	  B	  vaccine	  coverage	  has	  in	  a	  global	  setting	  increased	  rapidly.	  Data	  from	  2015	  show	  a	  global	  
coverage	  with	  3	  doses	  of	  the	  hepatitis	  B	  vaccine	  at	  82%,	  and	  92%	  in	  Western	  Pacific.	  	  This	  is	  a	  result	  of	  
including	  hepatitis	  B	  vaccine	  into	  children	  immunization	  programs	  in	  184	  countries	  [51].	  The	  
combination	  of	  HBIG	  and	  a	  monovalent	  hepatitis	  B	  vaccine	  given	  within	  24	  hours	  of	  birth	  has	  reduced	  the	  
rate	  of	  MTCT	  from	  >90%	  to	  <10%	  [4,	  20].	  Literature	  points	  out	  that	  the	  dose	  should	  be	  given	  as	  soon	  as	  
possible	  after	  birth	  and	  some	  guidelines	  operate	  with	  12	  hours	  postpartum	  [40].	  It	  is	  important	  to	  notice	  
that	  HBIG	  is	  not	  an	  effective	  prevention	  strategy	  after	  48	  hours	  [48].	  	  WHO	  recommend	  both	  a	  
monovalent	  HBV	  vaccination	  within	  24	  h	  of	  birth,	  followed	  by	  two	  or	  three	  series,	  see	  table	  4	  [20].	  
	  
Table	  4.	  Recommended	  routine	  immunization	  for	  HBV	  for	  children	  
	  
A	  3	  dose	  vaccine	  (1	  monovalent	  birth	  dose	  followed	  by	  2	  monovalent	  or	  combined	  vaccine	  doses	  at	  the	  
time	  of	  DTP1	  and	  DTP3	  vaccine	  doses)	  is	  recommended.	  However,	  4	  doses	  may	  be	  given	  for	  
programmatic	  reasons	  (e.g.	  1	  monovalent	  birth-­‐dose	  followed	  by	  3	  monovalent	  or	  combined	  vaccine	  
doses	  with	  DTP	  vaccine	  doses).	  PEP	  for	  infants	  weighing	  less	  than	  2000	  grams	  include	  a	  dose	  at	  birth,	  
which	  is	  not	  counted	  toward	  a	  ≥3-­‐dose	  HepB	  vaccine	  series	  [20].	  
8.1.1	  Lifelong	  immunity-­‐	  the	  need	  of	  a	  booster	  dose?	  
	  
A	  “booster	  dose”	  is	  a	  term	  referring	  to	  a	  vaccination	  given	  some	  time	  after	  a	  primary	  vaccination	  series.	  
The	  aim	  is	  to	  provide	  a	  rapid	  protective	  immunity	  against	  a	  significant	  breakthrough	  hepatitis	  B	  virus	  
infection	  clinical	  disease	  or	  serological	  test	  positive	  for	  HBV.	  The	  question	  whether	  it	  is	  a	  need	  for	  a	  
booster	  dose,	  or	  not,	  have	  been	  posed	  several	  years	  back,	  at	  a	  time	  with	  limited	  data	  [52].	  European	  
Consensus	  Group	  on	  Hepatitis	  B	  Immunity	  published	  in	  the	  Lancet	  in	  2000	  that	  there	  is	  no	  need	  for	  a	  
booster	  dose	  in	  healthy,	  fully	  vaccinated	  individuals	  [53].	  	  In	  developing	  countries	  with	  high	  endemicity,	  
this	  new	  recommendations	  meant	  a	  great	  decrease	  in	  costs	  savings	  [52].	  Over	  the	  years,	  more	  data	  have	  
been	  published	  including	  longer	  post-­‐vaccination	  follow-­‐up	  studies	  and	  the	  results	  are	  supporting	  the	  
statement	  from	  year	  2000.	  A	  follow	  up	  study	  from	  Thailand	  of	  infants	  receiving	  PEP	  after	  WHO	  
guidelines,	  showed	  maintenance	  of	  immune	  memory	  and	  long-­‐term	  protection	  after	  22	  years,	  among	  
children	  that	  immunologically	  responded	  to	  the	  vaccine	  [54].	  Additionally,	  a	  similar	  result	  was	  obtained	  
	   Age	  of	  1st	  
dose	  
Doses	   Interval	  between	  doses	   Booster	  
dose	  
Considerations	  
1st	  to	  2nd	  	   2nd	  to	  3rd	  	   3rd	  to	  4th	  	  
Option	  1	   As	  soon	  as	  
possible	  after	  
birth	  (<24h)	  











High	  risk	  groups	  Option	  2	   As	  soon	  as	  
possible	  after	  
birth	  (<24h)	  













in	  a	  follow-­‐up	  study	  from	  Italy;	  immune	  memory	  for	  HBsAg	  persists	  beyond	  the	  time	  at	  which	  anti-­‐HBs	  
disappears	  [55].	  Presumably	  the	  immune	  memory	  persists	  through	  cellular	  immunity	  [50].	  The	  Journal	  of	  
Infectious	  Diseases	  published	  this	  year	  a	  30-­‐year	  follow-­‐up	  study	  from	  Alaska	  that	  concluded	  that	  a	  
booster	  dose	  is	  not	  needed,	  an	  overall	  of	  ≥94%	  seemed	  to	  be	  protected	  (had	  anti-­‐HBs	  	  ≥10	  mIU/mL	  
and/or	  responded	  to	  booster	  dose).	  Initial	  anti-­‐HBs	  level	  and	  age	  at	  vaccination	  seemed	  to	  play	  an	  
important	  role	  in	  the	  persistence	  of	  antibodies	  [49].	  However,	  despite	  these	  findings,	  it	  is	  still	  not	  
consensus	  about	  how	  long	  immune	  memory	  will	  last	  and	  whether	  a	  booster	  dose	  is	  needed	  or	  not	  [21].	  
Moreover,	  the	  so	  called	  “Alaska	  study”	  will	  continue	  to	  follow	  the	  participant	  at	  35	  years	  and	  announce	  
that	  they	  will	  also	  look	  into	  cellular	  mediated	  immunity,	  included	  to	  the	  more	  well	  studied	  humoral	  
immune	  memory,	  which	  is	  important	  “especially	  in	  individuals	  that	  lose	  anti-­‐HBs	  and	  fail	  to	  respond	  to	  a	  
booster	  dose”	  [21].	  
8.2	  Current	  guidelines	  in	  Norway	  by	  the	  Norwegian	  Institute	  of	  Public	  Health	  
	  
The	  incidence	  of	  acute	  hepatitis	  B	  in	  Norway	  has	  since	  1975	  decreased	  dramatically	  with	  an	  increase	  
around	  1995-­‐2004	  due	  to	  an	  outbreak	  among	  drug	  abusers.	  In	  the	  period	  2008-­‐2015	  there	  were	  no	  
reported	  cases	  of	  MTCT	  of	  HBV.	  Transmission	  between	  heterosexuals	  and	  through	  contaminated	  needles	  
were	  the	  main	  anticipated	  mode	  of	  transmission,	  with	  a	  total	  of	  14	  incidences	  out	  of	  19	  reported	  cases	  of	  
acute	  infections	  in	  Norway.	  According	  to	  the	  Norwegian	  Institute	  of	  Public	  Health,	  people	  in	  Norway	  with	  
another	  ethnical	  background	  has	  a	  chronic	  HBV	  infection	  due	  to	  perinatal	  transmission	  or	  transmission	  in	  
early	  childhood	  in	  their	  home	  country.	  In	  contrast,	  people	  born	  in	  Norway	  with	  a	  chronic	  HBV	  infection	  
are	  likely	  to	  have	  the	  infection	  due	  to	  injection	  of	  contaminated	  needles.	  In	  the	  annually	  report	  by	  
Norwegian	  Institute	  of	  Public	  Health	  published	  in	  2015,	  there	  was	  reported	  795	  new	  cases	  of	  hepatitis	  B.	  
Further	  it	  is	  estimated	  that	  about	  25,000-­‐30,000	  persons	  are	  chronic	  carriers,	  with	  a	  recent	  increase	  due	  
to	  immigration	  from	  medium-­‐	  and	  high-­‐endemic	  countries	  [31].	  According	  to	  Resistance	  against	  
Antivirals	  in	  Norway	  (RAVN)	  from	  2015,	  the	  majority	  of	  all	  new	  cases	  are	  among	  immigrants	  for	  Somalia,	  
Afghanistan,	  Vietnam,	  Thailand	  and	  Eritrea	  [56],	  but	  as	  previously	  mentioned,	  this	  has	  not	  led	  to	  any	  new	  
cases	  of	  MTCT	  since	  2008.	  
	  
WHO	  has	  since	  1991	  recommended	  all	  member	  countries	  to	  include	  the	  hepatitis	  B	  vaccine	  into	  their	  
national	  vaccination	  programs.	  However,	  the	  Nordic	  countries	  and	  Great	  Britten	  has	  decided	  to	  only	  
vaccinate	  groups	  at	  risk	  because	  of	  the	  low	  incidence	  of	  HBV	  infections	  [31].	  	  
8.2.1	  Pregnant	  and	  neonatal	  prophylaxis	  
	  
Norwegian	  Institute	  of	  Public	  Health	  recommends	  routine	  testing	  of	  pregnant	  women	  from	  medium-­‐	  and	  
high-­‐endemic	  countries.	  When	  testing	  pregnant	  women,	  both	  HBsAg	  and	  anti-­‐HBc	  should	  be	  screened	  for,	  
see	  table	  2	  for	  abbreviation.	  Pregnant	  women	  born	  in	  Norway	  is	  only	  recommended	  to	  go	  through	  
screening	  based	  on	  following	  indications,	  which	  also	  includes	  her	  sexual	  partner:	  
• Current	  or	  previous	  injection	  drug	  users	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• Received	  blood	  transfusion	  out	  of	  Norway	  
• Sexual	  contact	  with	  an	  injection	  user	  or	  bisexual	  man	  
• Exposed	  in	  a	  job	  related	  setting	  
• Previous	  hepatitis	  B	  infection	  
	  
The	  recommendations	  by	  Norwegian	  Institute	  of	  Public	  Health	  concerning	  PEP	  are	  more	  or	  less	  in	  
coherence	  with	  WHO	  guidelines.	  Newborns	  should	  receive	  HBIG	  and	  the	  first	  vaccination	  dose	  after	  birth,	  
followed	  by	  three	  doses	  at	  1,	  2	  and	  12	  months.	  Twelve	  to	  fifteen	  months	  after	  birth	  it	  is	  recommended	  
serological	  testing	  of	  HBsAg	  and	  anti-­‐HBc	  to	  look	  for	  MTCT	  despite	  prevention	  strategies.	  This	  includes	  
serological	  testing	  of	  anti-­‐HBs	  to	  see	  if	  a	  booster	  dose	  is	  necessary.	  A	  booster	  dose	  is	  recommended	  for	  
whom	  with	  antibody-­‐response	  <	  100	  IU/l	  after	  last	  vaccination	  dose.	  Breastfeeding	  is	  encouraged	  
throughout	  the	  period	  [48].	  
8.2.2	  Norwegian	  Childhood	  Immunization	  Program	  	  
	  
The	  hepatitis	  B	  vaccine	  is	  offered	  in	  the	  immunization	  program	  to	  children	  of	  parents	  from	  countries	  with	  
a	  high	  incidence	  of	  the	  disease.	  In	  addition,	  the	  vaccine	  is	  offered	  free	  of	  charge	  to	  other	  people	  who	  [48]	  
• Have	  an	  increased	  risk	  of	  becoming	  infected	  
• Have	  an	  increased	  risk	  of	  becoming	  chronic	  carriers	  if	  they	  become	  infected	  
	   	   	  	  
Already	  back	  in	  2008	  the	  Norwegian	  Institute	  of	  Public	  Health	  recommended	  reintroducing	  the	  hepatitis	  
B	  vaccine	  into	  the	  Childhood	  Immunization	  Program,	  as	  WHO	  recommends	  to	  its	  member	  countries.	  The	  
process	  started	  in	  spring	  2015	  and	  the	  vaccine	  will	  earliest	  be	  reintroduced	  in	  2017.	  The	  institute	  poses	  
multiple	  arguments	  why	  not	  only	  groups	  at	  risk	  should	  receive	  the	  vaccine.	  Increased	  globalization	  and	  
immigration	  from	  regions	  with	  medium-­‐	  or	  high-­‐endemic	  countries	  are	  among	  some.	  The	  vaccine	  is	  also	  
effective	  and	  there	  are	  a	  few	  reported	  side-­‐effects	  [57].	  
	   8.3	  Maternal	  screening	  methods	  
	  
The	  majority	  of	  pregnant	  women	  with	  CHB	  infection	  will	  be	  asymptomatic,	  thus	  they	  will	  be	  identified	  
through	  routine	  screening	  in	  the	  perinatal	  period	  [40].	  Centre	  for	  Disease	  Control	  and	  Prevention	  (CDC)	  
recommend	  testing	  for	  HBsAg	  in	  all	  pregnant	  women,	  including	  previously	  tested	  and	  vaccinated.	  There	  
are	  currently	  no	  screening	  methods	  with	  high	  sensitivity	  and	  specificity,	  to	  identify	  chronic	  carriers	  of	  
HBV	  pregnant,	  which	  are	  available	  in	  a	  low-­‐resource	  setting	  [8].	  Literature	  points	  out	  that	  such	  a	  method	  
should	  ideally	  capture	  all	  HBeAg-­‐positive	  women,	  but	  at	  a	  least	  women	  that	  are	  HBsAg	  positive.	  	  A	  study	  
from	  China	  in	  2012	  looked	  more	  into	  that	  the	  proportion	  screened	  is	  often	  suboptimum,	  and	  that	  the	  
prevention	  of	  MTCT	  failed	  at	  a	  level	  of	  identifying	  the	  positive	  mothers	  [58].	  
	  
An	  occult	  HBV	  infection,	  also	  called	  “window	  period”	  or	  “silent”	  form	  in	  phase	  5,	  is	  characterized	  by	  the	  
presence	  of	  HBV	  DNA	  without	  HBsAg.	  Most	  are	  also	  without	  the	  presence	  of	  HBV	  antibodies	  [20,	  59].	  It	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has	  important	  clinical	  significance	  in	  several	  conditions,	  e.g.	  in	  blood	  transfusion	  where	  HBsAg	  is	  used	  as	  
the	  sole	  marker	  of	  infection	  in	  donor	  populations	  [60].	  	  However	  this	  “window	  period”	  is	  not	  described	  in	  
literature	  as	  a	  problem	  when	  it	  comes	  to	  MTCT	  due	  to	  the	  low	  viral	  concentration	  in	  blood	  [31].	  
	   8.4	  Maternal	  vaccination	  strategies	  
	  
Unvaccinated	  HBsAg	  negative	  mothers	  in	  a	  setting	  at	  risk	  for	  transmission	  should	  initiate	  vaccination	  [9].	  
	   8.5	  Antiviral	  therapy	  
	  
Newly	  published	  literature	  [8]	  suggests	  a	  shift	  of	  focus	  to	  decrease	  MTCT	  of	  HBV	  by	  reduction	  of	  the	  
maternal	  viral	  concentrations	  before	  delivery.	  The	  ultimate	  goal	  in	  future	  is	  to	  completely	  eliminate	  the	  
virus,	  which	  to	  date	  is	  not	  achieved	  by	  current	  antiviral	  therapy.	  Complete	  eradication	  is	  difficult	  due	  to	  
the	  remaining	  cccDNA	  in	  the	  hepatocyte	  and	  the	  difficult	  induction	  of	  immune	  control	  of	  the	  virus	  [19].	  	  
As	  briefly	  touched	  upon	  earlier,	  studies	  points	  out	  that	  maternal	  concentrations	  of	  HBV	  DNA	  is	  the	  most	  
important	  risk	  factor	  of	  MTCT,	  with	  a	  cutoff	  of	  200	  000	  IU/mL	  (2	  x105	  IU/mL)	  [14,	  61].	  Given	  what	  we	  
know	  about	  the	  most	  common	  route	  of	  MTCT	  from	  exposure	  to	  maternal	  blood	  and	  secretions	  at	  delivery,	  
viral	  concentration	  in	  maternal	  blood	  is	  of	  great	  significance	  [20].	  The	  current	  immunoprophylaxis	  
regime	  fails	  in	  8-­‐32%	  whom	  mothers	  have	  high	  levels	  of	  viremia	  (>200	  000	  IU/mL),	  even	  when	  
administrated	  after	  the	  guidelines	  [62].	  According	  to	  AASLD	  guidelines	  there	  are	  only	  three	  antivirals	  
studied	  in	  pregnant	  women;	  lamivudine,	  telbivudine	  and	  tenofovir	  [45].	  Several	  studies	  can	  show	  results	  
of	  lowering	  the	  risk	  of	  HBV	  transmission	  when	  given	  antiviral	  treatment	  to	  high-­‐risk	  women	  along	  with	  
standard	  immunoprophylaxis	  [14,	  63].	  A	  retoperspectiv	  study	  from	  2013	  including	  pregnant	  women	  with	  
levels	  of	  HBV	  DNA	  >200	  000	  IU/mL	  and	  HBeAg	  positive	  that	  had	  been	  given	  tenofovir	  disoproxil	  
fumarate	  (TDF)	  during	  second	  and	  third	  trimester,	  reduced	  the	  perinatal	  transmission.	  Vaccine	  and	  HBIG	  
were	  administrated	  according	  to	  WHO	  guidelines	  [64].	  	  However	  literature	  points	  out	  that	  the	  levels	  of	  
HBV	  DNA	  could	  be	  further	  reduced	  if	  starting	  treatment	  earlier,	  but	  that	  there	  are	  insufficient	  data	  upon	  
the	  timing	  [12].	  A	  meta-­‐analysis	  published	  this	  year	  in	  Hepatology,	  included	  26	  studies	  and	  its	  findings	  
showed	  that	  antiviral	  therapy	  reduces	  MTCT	  in	  women	  with	  chronic	  HBV	  infection	  and	  high	  viral	  load	  
[65].	  
8.5.1	  Current	  recommendations	  by	  AASLD	  of	  CHB	  in	  pregnancy	  [45]	  
	  
• The	  infants	  of	  all	  HBsAg-­‐positive	  women	  should	  receive	  immunoprophylaxis	  (HBV	  vaccination	  ±	  
hepatitis	  B	  immunoglobulin,	  per	  WHO/Centers	  for	  Disease	  Control	  and	  Prevention	  
recommendations).	  
• Antiviral	  therapy	  was	  started	  at	  28-­‐32	  weeks	  of	  gestation	  in	  most	  of	  the	  studies.	  
• Antiviral	  therapy	  was	  discontinued	  at	  birth	  to	  3	  months	  postpartum	  in	  most	  of	  the	  studies.	  With	  
discontinuation	  of	  treatment,	  women	  should	  be	  monitored	  for	  ALT	  flares	  every	  3	  months	  for	  6	  
months.	  
• There	  are	  limited	  data	  on	  level	  of	  HBV	  DNA	  for	  which	  antiviral	  therapy	  is	  routinely	  recommended.	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The	  level	  of	  	  >200,000	  IU/mL	  (1	  million	  copies/mL)	  is	  a	  conservative	  recommendation.	  
• For	  pregnant	  women	  with	  immune-­‐active	  hepatitis	  B,	  treatment	  should	  be	  based	  on	  
recommendations	  for	  nonpregnant	  women.	  
• Breastfeeding	  is	  not	  contraindicated.	  These	  antivirals	  are	  minimally	  excreted	  in	  breast	  milk	  and	  are	  
unlikely	  to	  cause	  significant	  toxicity.	  The	  unknown	  risk	  of	  low-­‐level	  exposure	  to	  the	  infant	  should	  be	  
discussed	  with	  mothers.	  
• There	  are	  insufficient	  long-­‐term	  safety	  data	  in	  infants	  born	  to	  mothers	  who	  took	  antiviral	  agents	  
during	  pregnancy	  and	  while	  breastfeeding.	  
• C-­‐section	  is	  not	  indicated	  owing	  to	  insufficient	  data	  to	  support	  benefit.	  
Current	  recommendations	  recommends	  against	  the	  use	  of	  antiviral	  drugs	  in	  HBsAg-­‐positive	  pregnant	  
woman	  with	  an	  HBV	  DNA	  ≤200,000	  IU/mL	  [45].	  Present-­‐day	  drug	  labels	  do	  not	  recommend	  
breastfeeding	  in	  combination	  with	  TDF	  or	  lamivudine.	  However,	  studies	  show	  that	  the	  infants	  are	  
exposed	  to	  higher	  drug	  doses	  during	  pregnancy.	  Moreover	  TDF	  is	  one	  of	  the	  drugs	  included	  in	  the	  WHO	  
guidelines	  for	  breastfeeding	  in	  HIV-­‐positive	  mothers	  on	  antiretroviral	  treatment	  (ART)	  [66].	  	  AASLD	  
points	  out	  that	  the	  safety	  of	  lamivudine	  and	  tenofovir	  during	  breastfeeding	  has	  not	  been	  well	  studied	  in	  
women	  infected	  with	  CHB,	  but	  refers	  to	  data	  from	  the	  existing	  HIV	  literature	  [45].	  
8.5.2	  Are	  there	  any	  effects	  on	  obstetric	  or	  infant	  parameters?	  
	  
TDF	  or	  lamivudine	  given	  during	  second	  and	  third	  trimester	  has	  not	  shown	  any	  different	  in	  obstetric	  or	  
infant	  parameters,	  such	  as	  congenital	  abnormalities	  or	  neonatal	  growth	  centiles	  [63,	  65].	  The	  antiviral	  
drug	  tenofovir	  has	  neither	  showed	  any	  adverse	  outcome	  to	  mother	  or	  child	  [65].	  TDF	  given	  in	  first	  
trimester	  to	  1370	  women	  did	  not	  show	  any	  increase	  in	  birth	  defects	  according	  to	  Antiretroviral	  
Pregnancy	  Registry.	  
8.6	  Postpartum	  strategies	  
	  
Minimizing	  the	  exposure	  of	  the	  newborn	  to	  maternal	  serum	  and	  amniotic	  fluid	  after	  birth	  may	  reduce	  the	  
risk	  of	  HBV	  infection.	  It	  can	  be	  done	  by	  avoiding	  contact	  and	  cleaning	  the	  respiratory	  tract	  and	  skin	  of	  the	  
newborn	  [7].	  Administration	  of	  HBIG	  keeps	  the	  incidence	  of	  this	  mode	  of	  transmission	  low	  [12].	  	  However	  
immunoglobulin	  is	  not	  widely	  available	  due	  to	  out-­‐of-­‐hospital	  births	  and	  storage	  criteria.	  Moreover,	  it	  is	  
expensive,	  all	  obvious	  factors	  to	  take	  into	  consideration	  in	  resource-­‐limited	  countries	  [8].	  Knowledge	  
about	  the	  virus	  and	  vaccination	  guidelines	  is	  in	  literature	  also	  described	  as	  important	  factors	  of	  MTCT	  of	  
the	  virus	  [67]	  .	  Unskilled	  health	  attendants	  and	  home	  deliveries	  are	  both	  risk	  factors	  for	  infants	  to	  get	  
infections,	  thus	  education	  and	  access	  to	  health	  facilities	  play	  a	  role	  in	  the	  postpartum	  strategies	  to	  
prevent	  MTCT	  [68].	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8.7	  Preventing	  MTCT	  of	  HBV	  at	  a	  structural	  level:	  technical	  strategies	  to	  update	  national	  
strategies	  
	  
WHO	  published	  in	  May	  2015	  a	  review	  in	  the	  Journal	  of	  Viral	  hepatitis	  called	  “Where	  next	  for	  hepatitis	  B	  
and	  C	  surveillance?”	  The	  background	  for	  the	  publication	  was	  the	  need	  for	  an	  evaluation	  of	  future	  common	  
strategies,	  e.g.	  case	  reporting.	  Case	  reporting	  was	  stated	  as	  a	  fundament	  for	  comprehensive	  epidemiologic	  
assessments	  of	  the	  burden	  of	  hepatitis	  B	  and	  C,	  allowing	  decision-­‐makers	  to	  maximize	  the	  interventions	  
against	  the	  burden	  of	  disease.	  The	  variability	  in	  reported	  cases	  including	  sources	  of	  data,	  such	  as	  
serologic	  status,	  reflects	  the	  difference	  in	  testing	  and	  reporting	  practices.	  The	  review	  uses	  the	  lack	  of	  
differentiation	  between	  an	  acute	  and	  chronic	  HBV	  infection	  as	  an	  example.	  Moreover	  WHO	  emphasizes	  
that	  the	  public	  health	  response	  to	  hepatitis	  B	  (and	  C)	  has	  been	  “disproportionately	  small	  in	  relation	  to	  the	  
enormous	  burden	  of	  disease	  presented	  by	  these	  infections	  and	  in	  comparison	  with	  other	  communicable	  
diseases	  with	  a	  similar	  disease	  burden”.	  	  WHO	  highlighted	  the	  lack	  of	  epidemiological	  estimates	  as	  one	  of	  
the	  reasons	  why	  prevention	  and	  treatment	  strategies	  have	  been	  in	  variable	  quality.	  However,	  as	  the	  
review	  discuss,	  it	  is	  worth	  mentioning	  that	  the	  surveillance	  of	  HBV	  is	  more	  difficult	  than	  other	  diseases.	  
The	  review	  points	  out	  many	  asymptomatic	  individuals,	  availability	  of	  testing	  services	  and	  the	  complex	  
laboratory	  diagnosis	  as	  some	  of	  the	  difficulties	  [69].	  WHO	  published	  in	  September	  2015	  a	  technical	  report	  
to	  “provide	  guidance	  to	  public	  health	  professionals	  asked	  with	  managing	  a	  response	  to	  viral	  hepatitis”.	  The	  
manual	  is	  still	  provisorial	  and	  will	  be	  presented	  to	  the	  World	  Health	  Assembly	  in	  2016	  for	  adoption	  by	  
Member	  States	  [70].	  	  
	  
One	  other	  important	  aspect	  to	  highlight	  is	  the	  actual	  use	  and	  implementations	  of	  the	  guidelines.	  Despite	  
global	  guidelines	  published	  by	  WHO,	  national	  recommendations	  and	  routine	  practice	  varies.	  It	  is	  
estimated	  that	  in	  2014	  half	  of	  all	  countries	  were	  following	  the	  recommendations	  by	  WHO.	  There	  are	  
different	  explanations,	  and	  the	  problems	  are	  somehow	  complex.	  One	  aspect	  pointed	  out	  is	  the	  availability,	  
including	  limitation	  in	  storage,	  and	  costs	  of	  HBV	  monovalent	  vaccine	  and	  HBIG.	  This	  affects	  especially	  less	  
developed	  countries	  [8]	  
	  
Looking	  at	  Norwegian	  guidelines	  published	  by	  the	  Norwegian	  Institute	  of	  Public	  Health	  concerning	  case	  
reporting	  of	  the	  virus,	  the	  procedure	  is	  quite	  clear.	  The	  hepatitis	  B	  virus	  is	  classified	  as	  a	  group	  A	  disease	  
which	  means	  that	  the	  patient	  full	  identity	  should	  be	  registered	  at	  Norwegian	  Surveillance	  System	  for	  
Communicable	  Diseases	  (MSIS),	  including	  both	  acute	  and	  chronic	  carriers.	  The	  criteria	  are	  based	  on	  
laboratory	  techniques	  of	  either	  one,	  or	  in	  combination,	  of	  the	  following	  tests:	  HBsAg,	  HBeAg,	  HBV-­‐DNA	  
and	  anti-­‐HBc	  IgM	  [31].	  
	  
9.	  Factors	  associated	  with	  failure	  to	  PEP	  
	  
There	  are	  no	  quick	  answer	  to	  why	  PEP	  sometimes	  fails.	  On	  one	  hand,	  despite	  timely	  prophylaxis,	  the	  
MTCT	  of	  HBV	  occur	  in	  5-­‐15%,	  on	  the	  other	  hand,	  there	  are	  multiple	  factor	  associated	  with	  deviation	  from	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the	  PEP	  guidelines.	  Failure	  to	  PEP	  despite	  of	  timely	  treatment	  with	  profylaxis	  is	  associated	  with	  maternal	  
HBeAg	  positivity,	  high	  HBV	  DNA	  levels,	  nonresponse	  to	  the	  vaccine,	  and	  rarely,	  HBV	  mutations	  [9].	  	  As	  
pointed	  out	  earlier,	  AASLD	  explains	  the	  failure	  as	  a	  result	  of	  HBeAg-­‐	  positive	  mothers	  with	  a	  viral	  load	  
greater	  than	  200	  000	  IU/mL	  [45].	  Delay	  in	  receipt	  of	  the	  HepB	  birth	  dose,	  failure	  to	  complete	  the	  vaccine	  
series	  and	  failure	  to	  receive	  HBIG	  are	  some	  of	  the	  deviations	  from	  the	  guidelines	  [9].	  A	  deeper	  
understanding	  of	  PEP	  failure,	  with	  focus	  on	  two	  high-­‐endemic	  countries	  will	  be	  presented	  below.	  
	  
10.	  	  Perinatal	  transmission	  of	  HBV	  in	  Vietnam	  and	  Cambodia:	  An	  introduction	  to	  two	  
high-­‐endemic	  countries	  	  
	  
In	  Asia,	  and	  in	  particular	  in	  highly	  endemic	  East	  Asia,	  vertical	  transmission	  during	  the	  perinatal	  period	  is	  
the	  main	  cause	  of	  the	  transmission	  of	  HBV.	  	  The	  region	  has	  one	  of	  the	  worlds	  highest	  prevalence	  of	  the	  
virus	  (>5%)	  [20]	  and	  the	  virus	  is	  one	  of	  the	  major	  infectious	  cause	  of	  death	  in	  the	  region,	  ahead	  of	  
malaria,	  tuberculosis	  and	  HIV	  [5].	  As	  previously	  described,	  MTCT	  occurs	  in	  50%	  of	  unvaccinated	  children	  
with	  HBsAg	  positive	  mothers.	  90%	  of	  these	  will	  develop	  to	  chronic	  carriers,	  with	  the	  complications	  that	  
follow	  [6].	  In	  contrast,	  <5%	  of	  the	  horizontal	  transmissions	  to	  adults,	  leads	  to	  chronic	  carriers	  [4].	  The	  
regional	  goal	  for	  Western	  Pacific	  by	  2017	  of	  reducing	  the	  prevalence	  of	  hepatitis	  B	  chronic	  infections	  to	  
less	  than	  1	  %	  among	  children	  has	  been	  achieved.	  Even	  though	  this	  means	  an	  89%	  reduction	  in	  prevalence	  
compared	  to	  the	  period	  prior	  to	  vaccine	  introduction	  and	  the	  averment	  of	  seven	  million	  hepatitis	  related	  
deaths,	  there	  are	  still	  great	  challenges	  and	  differences	  among	  countries	  within	  the	  region.	  Vaccination	  
coverage	  according	  to	  guidelines	  and	  birth	  dose	  within	  24	  hours	  is	  pointed	  out	  to	  be	  the	  main	  reason	  for	  
that,	  with	  Vietnam	  as	  one	  of	  the	  countries	  with	  the	  highest	  number	  of	  perinatal	  infections	  [5].	  
	  
It	  is	  estimated	  that	  9%	  of	  the	  total	  population	  in	  Cambodia	  have	  a	  chronic	  disease.	  Seroprevalenses	  show	  
great	  provincial	  differences	  in	  HBsAg-­‐positive	  children,	  ranging	  from	  0,33	  to	  3,45,	  with	  higher	  
prevalences	  in	  rural	  areas	  [71].	  Figure	  5	  and	  6	  present	  the	  vaccine	  coverage	  in	  Cambodia	  and	  Vietnam,	  
based	  on	  data	  for	  WHO	  databases	  [72,	  73].	  The	  vaccines	  was	  introduces	  in	  Cambodia	  in	  2006	  [71]	  and	  by	  
2014	  the	  country	  had	  97%	  coverage	  of	  3-­‐dose	  hepatitis	  B	  vaccine	  (HepB3)	  and	  87%	  coverage	  of	  birth	  
dose	  (HepB_BD).	  Vietnam,	  on	  the	  other	  hand,	  introduced	  the	  3-­‐dose	  vaccine	  nationwide	  in	  2002	  and	  birth	  
dose	  in	  2003	  [74]	  and	  data	  from	  2014	  reveals	  coverage	  of	  95%	  of	  HepB3	  and	  55%	  of	  HepB_BD.	  The	  





Figure	  5.	  	  Vaccine	  coverage	  in	  Cambodia	  between	  2007	  and	  2014	  
	  
	  
Figure	  6.	  	  Vaccine	  coverage	  in	  Vietnam	  between	  2005	  and	  2014	  
	  
As	  figure	  6	  indicates,	  the	  country	  has	  confronted	  some	  challenges	  along	  the	  way,	  looking	  at	  the	  incidences	  
in	  2007	  and	  2013	  with	  particular	  interest.	  Vaccine	  published	  in	  2016	  an	  article	  that	  looked	  further	  into	  
why	  there	  was	  a	  substantial	  reduction	  in	  hepatitis	  B	  vaccination	  coverage	  during	  the	  particular	  period	  
and	  estimated	  the	  extent	  of	  impacts.	  It	  was	  estimated	  that	  130,675	  chronic	  HBV	  infections	  and	  25,197	  
HBV-­‐related	  deaths	  would	  occur	  in	  children	  born	  in	  2013	  due	  to	  the	  decrease	  in	  coverage.	  The	  article	  
points	  out	  public	  concern	  over	  vaccine	  safety	  and	  the	  media	  coverage	  as	  the	  main	  cause	  of	  the	  incidence	  
[75].	  
	  
Literature	  empathizes	  that	  routine	  newborn	  HBV	  vaccination	  in	  Vietnam	  is	  highly	  cost-­‐effective	  from	  the	  
payer’s	  perspective	  and	  cost-­‐saving	  from	  both	  societal	  and	  health	  care	  perspective	  [76].	  The	  
complications	  to	  a	  chronic	  infection	  put	  a	  substantial	  financial	  burden	  not	  only	  at	  an	  individual	  level,	  put	  
also	  on	  the	  Vietnamese	  health	  care	  system	  and	  society	  [28].	  Home	  births	  in	  Cambodia	  is	  common	  and	  
children	  born	  at	  home	  without	  a	  skilled	  birth	  attendant	  will	  have	  two	  times	  the	  chance	  of	  missing	  a	  birth-­‐
dose	  within	  24	  hours,	  compared	  to	  those	  born	  in	  proper	  health	  facilities.	  The	  chance	  is	  even	  greater	  if	  the	  











































skilled	  birth	  attendants.	  Another	  important	  aspect	  concerning	  factors	  associated	  with	  under-­‐vaccination	  
in	  Cambodia	  is	  the	  mother’s	  educational	  level.	  If	  the	  mother	  had	  received	  primary	  or	  secondary	  school,	  
there	  are	  30%	  less	  of	  a	  chance	  of	  unvaccination	  with	  timely	  birth	  dose	  (<24	  hours).	  	  However	  Cambodia	  
Ministry	  of	  Health	  has	  acknowledged	  the	  problems	  with	  out-­‐of-­‐hospital	  birth	  and	  has	  among	  others	  
implemented	  simple	  injection	  devices	  (e.g.	  Uniject)	  to	  reach	  infants	  born	  at	  home.	  Additionally	  the	  true	  
number	  of	  children	  receiving	  appropriate	  vaccination	  is	  often	  unknown	  and	  national	  serosurveys	  are	  
needed.	  Furthermore,	  training	  and	  education	  of	  skilled	  birth	  attendants	  are	  needed	  [71].	  Vietnam	  has	  
faced	  some	  of	  the	  similar	  difficulties	  upon	  timing	  and	  coverage	  and	  their	  national	  immunization	  program	  
has	  raised	  awareness	  over	  the	  importance	  of	  a	  birth-­‐dose	  holding	  seminars	  among	  public	  health	  decision	  
makers,	  re-­‐training	  health-­‐care	  works	  and	  initiation	  of	  awareness	  campaigns.	  Another	  important	  aspect	  
pointed	  out	  is	  the	  need	  to	  improve	  access	  and	  demand	  to	  poor	  ethnic	  groups	  with	  high	  HBsAg	  often	  living	  
in	  remote	  areas	  [74].	  In	  addition,	  blood	  safety	  and	  sterilization	  in	  medical	  settings	  should	  be	  further	  
improved	  to	  avoid	  parenteral	  transmission	  [77].	  
	  
Despite	  all	  the	  challenges,	  hepatitis	  B	  prevalence	  among	  children	  has	  dramatically	  decreased.	  However	  
looking	  into	  the	  future,	  vaccination	  at	  birth	  with	  the	  timely	  birth	  dose	  and	  complete	  infant	  hepatitis	  B	  
vaccination	  series,	  is	  still	  number	  one	  prevention	  strategies	  of	  MTCT	  in	  the	  region.	  Additional	  strategies	  
such	  as	  antiviral	  therapy	  for	  pregnant	  women	  may	  be	  necessary	  in	  high	  endemic	  countries	  such	  as	  
Vietnam	  and	  Cambodia	  where	  perinatal	  transmission	  still	  occurs.	  At	  a	  regional	  level,	  new	  goals	  beyond	  
2017	  should	  be	  completed.	  Total	  elimination	  of	  MTCT	  should	  be	  in	  reach.	  The	  Western	  Pacific	  Region	  has	  
this	  year	  launched	  plans	  to	  hepatitis	  prevention	  by	  developing	  a	  regional	  action	  plan	  that	  includes	  




It	  has	  become	  obvious	  that	  hepatitis	  B	  is	  a	  major	  public	  health	  problem	  and	  should	  be	  recognized	  as	  a	  
burden	  of	  disease	  in	  line	  with	  tuberculosis,	  HIV	  and	  malaria,	  not	  only	  at	  an	  individual	  level,	  but	  also	  at	  a	  
socio-­‐economic	  level.	  	  This	  assignment	  has	  focused	  on	  the	  consequence	  of	  MTCT	  of	  hepatitis	  B	  and	  looked	  
into	  the	  prevention	  strategies	  as	  an	  important	  component	  of	  reducing	  the	  global	  burden	  of	  CHB	  
infections.	  	  It	  appears	  like	  vertical	  transmission	  of	  the	  virus	  is	  the	  major	  route	  of	  transmission	  in	  less	  
developed	  countries,	  while	  horizontal	  transmission	  dominate	  in	  countries	  such	  as	  Norway.	  However	  
some	  researchers	  put	  a	  question	  mark	  whether	  MTCT	  is	  the	  most	  important	  factor	  for	  developing	  a	  
persistent	  HBV	  infection.	  It	  could	  be	  overestimated	  as	  different	  genotypes	  and	  genetic	  polymorphism	  
might	  contribute	  to	  higher	  prevalence	  in	  East	  Asia	  compared	  to	  Europe.	  	  	  
	  
One	  of	  the	  challenges	  with	  MTCT	  is	  that	  the	  risk	  of	  chronicity	  is	  inversely	  proportional	  with	  age	  and	  most	  
of	  the	  newborns	  (90%),	  to	  hepatitis	  B	  positive	  mothers,	  will	  get	  the	  virus	  without	  any	  prevention	  
strategies.	  Moreover,	  infection	  in	  infancy	  is	  usually	  asymptomatic	  until	  later	  in	  life,	  at	  a	  time	  where	  the	  
virus	  has	  caused	  severe	  liver	  disease.	  Clinically	  its	  impossible	  to	  differentiate	  the	  virus	  from	  other	  virus-­‐
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caused	  hepatitis,	  neither	  distinguish	  between	  an	  acute	  and	  chronic	  infection,	  hence	  laboratory	  confirming	  
is	  essential.	  However,	  hepatitis	  B	  is	  a	  resource-­‐demanding	  virus	  to	  diagnose.	  There	  are	  currently	  no	  
screening	  methods	  available	  in	  resource-­‐limited	  settings	  with	  sufficient	  test	  properties	  to	  capture	  HBsAg-­‐
,	  and	  ideally	  also	  HBeAg-­‐positive	  women.	  The	  result	  is	  often	  a	  suboptimum	  proportion	  been	  screened	  and	  
the	  prevention	  of	  MTCT	  fail	  at	  a	  level	  of	  identifying	  the	  positive	  mothers.	  Bearing	  both	  the	  diagnostic	  and	  
screening	  challenges	  in	  mind	  while	  looking	  at	  the	  possibilities	  for	  treatment,	  status	  quo	  is	  unfortunately	  
that	  there	  are	  no	  definite	  treatment	  to	  cure	  the	  infected	  mother	  or	  child	  from	  hepatitis	  B,	  thus	  vaccination	  
is	  essential	  to	  prevent	  MTCT	  of	  the	  virus.	  The	  vaccination	  is	  cost-­‐effective	  and	  with	  few	  reported	  side-­‐
effects,	  however	  it	  has	  to	  be	  administered	  timely	  and	  with	  proper	  number	  of	  doses	  to	  accomplish	  
complete	  prophylaxis.	  Moreover	  GAVI	  don’t	  support	  the	  monovalent	  dose,	  which	  makes	  is	  less	  available.	  
The	  advisable	  immunoglobulin,	  on	  the	  other	  hand,	  is	  both	  expensive	  and	  requires	  storage	  in	  cold	  
environment,	  obviously	  making	  it	  less	  available	  in	  resource	  limited	  countries.	  	  
	  	  	  
Looking	  at	  the	  different	  modes	  of	  transmission	  of	  the	  virus	  it	  is	  evident	  that	  less	  developed	  countries	  
have	  greater	  challenges.	  However	  it	  is	  easy	  to	  fall	  into	  the	  same	  old	  conclusion	  of	  lack	  of	  infrastructure,	  
history	  of	  poor	  political	  governance,	  corruption	  and	  economic	  challenges.	  It´s	  very	  general	  and	  count	  for	  
almost	  all	  global	  health	  problems.	  Vietnam	  and	  Cambodia	  have	  higher	  rates	  of	  out-­‐of-­‐hospital	  births,	  
challenges	  concerning	  skilled	  health	  workers	  and	  appropriate	  antenatal	  care,	  poor	  health	  facilities,	  
poverty	  and	  difficulties	  with	  establishing	  national	  serosurveys,	  essential	  for	  national	  guidelines	  and	  
policies.	  One	  factor	  is	  often	  leading	  to	  another,	  and	  all	  factors	  are	  pointed	  out	  to	  negatively	  affect	  the	  
extremely	  important	  birth	  dose,	  given	  within	  24	  hours.	  With	  the	  risk	  of	  generalizing,	  implementing	  these	  
challenges	  into	  other	  resource-­‐limited	  countries	  seems	  reasonable.	  Furthermore,	  WHO	  estimates	  that	  
only	  half	  of	  all	  countries	  were	  following	  their	  recommendations	  in	  2014,	  understandable	  taking	  the	  
situation	  in	  Vietnam	  and	  Cambodia	  into	  consideration.	  However,	  this	  assignment	  has	  been	  an	  eye-­‐opener	  
to	  how	  intricate	  the	  prevention	  of	  MTCT	  can	  be,	  things	  are	  often	  more	  complicated	  than	  they	  seemingly	  
appears	  to	  be.	  This	  has	  might	  become	  a	  weakness,	  understanding	  MTCT	  goes	  beyond	  a	  few	  headlines	  and	  
the	  way	  it	  is	  portrayed	  in	  this	  assignment	  is	  probably	  very	  simplified,	  important	  aspect	  might	  have	  been	  
excluded	  due	  to	  lack	  of	  literature	  or	  poor	  research	  strategy.	  
Concerning	  vaccination	  coverage,	  estimates	  by	  WHO	  show	  that	  these	  two	  countries	  are	  going	  in	  the	  right	  
direction,	  however	  they	  have	  still	  huge	  challenges	  and	  every	  day	  thousands	  of	  children	  develop	  chronicity	  
and	  will	  be	  needed	  resource	  demanding	  follow-­‐up	  and	  treatment	  in	  many	  years	  to	  come.	  
	  
Looking	  at	  the	  WHO	  and	  CDC	  guidelines,	  recommendations	  regarding	  the	  vaccine	  should	  be	  better	  
supported	  by	  research.	  Research	  gaps	  have	  become	  clear,	  and	  there	  are	  gaps	  between	  current	  knowledge	  
and	  practice,	  e.g.	  concerning	  a	  booster	  dose.	  There	  is	  a	  need	  of	  longitudinal	  cohort	  studies	  in	  under-­‐
researched	  populations	  such	  as	  children,	  young	  adults	  and	  pregnant	  women	  with	  CHB.	  Some	  is	  obvious	  
difficult	  to	  perform	  due	  to	  ethnical	  limitations,	  others	  could	  be	  a	  consequence	  of	  less	  profit	  in	  research	  
concerning	  health	  related	  questions	  in	  resource-­‐limited	  countries.	  The	  expensive	  HBIG	  has	  been	  
questioned;	  the	  mechanism	  and	  benefits	  are	  not	  well	  documented.	  Lowering	  the	  mothers	  viral	  load	  (VL)	  
with	  antiviral	  treatment	  before	  delivery	  might	  replace	  the	  HBIG	  in	  future,	  but	  the	  risks	  and	  benefits	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during	  pregnancy	  and	  breastfeeding	  needs	  additional	  surveillance.	  Whether	  we	  need	  a	  booster	  dose	  or	  
not	  is	  also	  questioned,	  both	  highly	  resource	  demanding	  measures.	  The	  mechanism	  concerning	  why	  
neonates	  develop	  CHB	  infection	  is	  still	  unclear,	  a	  central	  mechanism	  to	  understand	  MTCT.	  Further	  
research	  concerning	  both	  mechanism	  of	  the	  transmission	  and	  development	  into	  chronicity	  and	  
population	  based	  surveys	  are	  needed.	  
	   	  
12.	  Conclusion	  	  
Throughout	  the	  process	  of	  writing	  this	  assignment	  it	  became	  clear	  that	  the	  focus	  on	  MTCT	  of	  hepatitis	  B	  
is	  disproportionately	  small	  in	  relation	  to	  the	  enormous	  burden	  of	  disease	  presented	  by	  the	  virus.	  Despite	  
the	  heavy	  burden	  of	  HBV-­‐related	  deaths,	  new	  infections	  can	  effectively	  be	  prevented	  through	  timely	  
completion	  of	  three	  doses	  hepatitis	  B	  vaccination	  and	  administration	  of	  HBIG.	  Number	  one	  priority	  for	  
future	  strategies	  to	  combat	  MTCT	  will	  be	  to	  increase	  the	  coverage,	  with	  focus	  on	  increasing	  compliance	  of	  
the	  birth	  dose.	  Improving	  health	  system	  infrastructure,	  raising	  awareness	  in	  the	  general	  population,	  
increase	  the	  vaccine	  availability	  are	  among	  some	  of	  the	  key	  strategies.	  Continued	  public	  health	  efforts	  to	  
control	  transmission	  of	  HBV	  by	  prevention	  programs	  and	  effective	  strategies	  to	  screen	  and	  identify	  
positive	  mothers,	  monitor,	  and	  provide	  effective	  treatment	  for	  mothers	  with	  chronic	  infection,	  are	  
necessary	  to	  reduce	  and	  eliminate	  MTCT	  of	  HBV.	  Lowering	  maternal	  HBV	  DNA	  levels	  of	  the	  virus	  to	  the	  
minimum	  during	  third	  semester	  of	  pregnancy	  are	  a	  key	  factor,	  thus	  supplementary	  evaluations	  of	  
antiviral	  treatment	  is	  needed.	  Further	  research	  is	  needed	  to	  guide	  future	  policy	  recommendation.	  This	  
assignment	  can	  hopefully	  contribute	  to	  put	  focus	  on	  the	  global	  burden	  of	  HBV	  and	  prevention	  strategies	  
and	  may	  be	  the	  starting	  point	  for	  an	  article	  in	  a	  Norwegian	  paper	  or	  journal	  regarding	  the	  possible	  
reintroduction	  of	  the	  HepB	  vaccine	  into	  the	  Children	  Immunization	  Program	  in	  2017.	  
Finally,	  as	  long	  as	  the	  prevalence	  of	  the	  virus	  remains	  high	  in	  East	  Asia	  it	  will	  be	  a	  constant	  pool	  of	  
potentially	  transmissions	  from	  mother	  to	  child.	  To	  combat	  the	  spread	  of	  the	  virus	  at	  a	  global	  level,	  we	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